

# Practitioner's Manual

An Informational Outline of the Controlled Substances Act

\_\_\_\_\_

#### Joseph T. Rannazzisi

Deputy Assistant Administrator Office of Diversion Control

#### Mark W. Caverly

Chief, Liaison and Policy Section

This manual has been prepared by the Drug Enforcement Administration, Office of Diversion Control, to assist practitioners (physicians, dentists, veterinarians, and other registrants authorized to prescribe, dispense, and administer controlled substances) in their understanding of the Federal Controlled Substances Act and its implementing regulations as they pertain to the practitioner's profession.

-----

# Table of Contents

### **Section I - Introduction**

Disclaimer 1	l
Authorization for Public Dissemination	
Message from the Administrator	
Preface	
Section II – General Requirements	
Schedules of Controlled Substances. 5	5
Schedule I Substances 5	5
Schedule II Substances 5	
Schedule III Substances 6	5
Schedule IV Substances.	
Schedule V Substances 6	5
Registration Requirements	
Application for Registration	
Certificate of Registration	
Registration Renewals9	
Change of Business Address11	l
Termination of Registration	l
Denial, Suspension or Revocation of Registration	l
Practitioner's Use of a Hospital's DEA Registration Number	
Inappropriate Use of the DEA Registration Number	2
Exemption of Federal Government Practitioners from Registration	
Section III – Security Requirements	
Required Controls14	1
Safeguards for Prescribers	
Section IV – Recordkeeping Requirements	
Recordkeeping Requirements. 16 Inventory. 16	
Disposal of Controlled Substances	7

------

# Table of Contents (continued)

## **Section V – Valid Prescription Requirements**

	Requirements. 18 May Issue. 18
	ose of Issue
	Substances 19
	ls
	nce of Multiple Prescriptions for Schedule II Substances
	mile Prescriptions for Schedule II Substances
	ptions for Schedule II Facsimile Prescriptions
	-V Substances 21
	ls
	mile Prescriptions for Schedule III-V Substances
	phone Authorization for Schedule III-V Prescriptions
	a Controlled Substance to Persons Outside the U.S
Section V	I – Opioid (Narcotic) Addiction Treatment Programs
Opioid (Nar	cotic) Addiction Treatment Programs
${f A}$ ppendic	ees
Appendix A	CSA and CFR Definitions
Appendix B	Questions and Answers
Appendix C	Summary of Controlled Substances Act Requirements32
Appendix D	Internet Resources. 33
Appendix E	DEA Diversion Field Office Locations
Appendix F	Small Business and Agriculture Regulatory Enforcement
	Ombudsman
Appendix G	
Appendix H	
	Form 41 - Registrants Inventory of Drugs Surrendered
	Form 106 – Report of Theft or Loss of Controlled Substances
	Form 222 - U.S. Official Order Form for Controlled Substances47
	Form 224 – Application for Registration
	Form 224a - Renewal Application for Registration
DEA	Form 363 - Application for Registration Under the Narcotic
	Addict Treatment Act of 1974
DEA	Form 363a – Renewal for Registration Under the Narcotic Addict Treatment Act of 1974

\_\_\_\_\_\_

### **SECTION I - INTRODUCTION**

This practitioner's manual is intended to summarize and explain the basic requirements for prescribing, administering, and dispensing controlled substances under the Controlled Substances Act (CSA), 21 USC 801-890, and the DEA regulations, Title 21, Code of Federal Regulations (CFR), Parts 1300 to 1316. Pertinent citations to the law and regulations are included in this manual

Printed copies of the CFR and the complete regulations implementing the CSA may be obtained from:

Superintendent of Documents U.S. Government Printing Office Washington, D.C. 20402

Both the CFR and the *Federal Register* (which includes proposed and final regulations implementing the CSA) are available on the Internet through the U.S. Government Printing Office (GPO) website. This website, which provides information by section, citation and keywords, can be accessed at:

www.gpoaccess.gov/cfr/index.html

Unofficial copies of pertinent CFR citations may be found at:

www.DEAdiversion.usdoj.gov

This practitioner's manual may also be found on the Internet at DEA's Web Site (under "publications"):

www.DEAdiversion.usdoj.gov

Should any pertinent provisions of the law or regulations be modified in the future, DEA will issue a revised electronic version of this document, which will be published on the DEA Diversion Website

If you encounter errors in this document, please notify:

Editor, DEA Practitioner's Manual c/o DEA, Office of Diversion Control Liaison and Policy Section Washington, D.C. 20537

Inquiries regarding topics within this document may be addressed to your local DEA field office (listed in Appendix E) or the address above.

\_\_\_\_\_

### This Document is Authorized for Public Dissemination

All material in this publication is in the public domain and may be reproduced without the express permission of the Drug Enforcement Administration.

-----

### **Message from the Administrator**

The Drug Enforcement Administration is pleased to provide this updated edition of the 1990 Practitioner's Manual to assist you in understanding your responsibilities under the Controlled Substances Act (CSA) and its implementing regulations. This manual will help answer questions that you may encounter in your practice and provide guidance in complying with federal requirements.

DEA remains committed to the 2001 Balanced Policy of promoting pain relief and preventing abuse of pain medications. In enforcing the CSA, it is DEA's responsibility to ensure drugs are not diverted for illicit purposes. Unfortunately, this country is now experiencing an alarming prescription drug abuse problem:

- Today, more than 6 million Americans are abusing prescription drugs—that is more than the number of Americans abusing cocaine, heroin, hallucinogens, and inhalants, combined.
- Researchers from the Centers for Disease Control and Prevention report that opioid
  prescription painkillers now cause more drug overdose deaths than cocaine and
  heroin combined.
- Today more new drug users have begun abusing pain relievers (2.4 million) than marijuana (2.1 million) or cocaine (1.0 million).

It is more important now than ever to be vigilant in preventing the diversion and abuse of controlled substances. This manual will help you do that by listing some safeguards you can take to prevent such diversion. It also explains registration, recordkeeping, and valid prescription requirements.

As a practitioner, your role in the proper prescribing, administering, and dispensing of controlled substances is critical to patients' health and to safeguarding society against the diversion of controlled substances. DEA is committed to working jointly with the medical community to ensure that those in need are cared for and that legitimate controlled substances are not being diverted for illegal use.

Karen P. Tandy Administrator September 2006

-----

#### **Preface**

The Drug Enforcement Administration (DEA) was established in 1973 to serve as the primary federal agency responsible for the enforcement of the Controlled Substances Act (CSA). The CSA sets forth the federal law regarding both illicit and licit (pharmaceutical) controlled substances. With respect to pharmaceutical controlled substances, DEA's statutory responsibility is twofold: to prevent diversion and abuse of these drugs while ensuring an adequate and uninterrupted supply is available to meet the country's legitimate medical, scientific, and research needs. In carrying out this mission, DEA works in close cooperation with state and local authorities and other federal agencies.

Under the framework of the CSA, the DEA is responsible for ensuring that all controlled substance transactions take place within the "closed system" of distribution established by Congress. Under this "closed system," all legitimate handlers of controlled substances – manufacturers, distributors, physicians, pharmacies, and researchers – must be registered with DEA and maintain strict accounting for all distributions.

To carry out DEA's mission effectively, this 2006 Practitioner's Manual seeks to aid DEA registrants in complying with the CSA and its implementing regulations. The DEA understands that it can best serve the public interest by working with practitioners to prevent diversion of legal pharmaceutical controlled substances into the illicit market.

The federal controlled substances laws are designed to work in tandem with state controlled substance laws. Toward this same goal, DEA works in close cooperation with state professional licensing boards and state and local law enforcement officials to ensure that pharmaceutical controlled substances are prescribed, administered, and dispensed for legitimate medical purposes in accordance with federal and state laws. Within this cooperative framework, the majority of investigations into possible violations of the controlled substances laws are carried out by state authorities. However, DEA also conducts investigations into possible violations of federal law as circumstances warrant.

In the event a state board revokes the license of a practitioner, the DEA will take action and request a voluntary surrender of the practitioner's DEA registration. If the practitioner refuses to voluntarily surrender the registration, the DEA will pursue administrative action to revoke the DEA registration. The DEA may also pursue judicial action if there is sufficient evidence of illegal distribution or significant recordkeeping violations. All such actions are intended to deny the practitioner the means to continue to divert or abuse controlled substances as well as to protect the health and safety of the public and the practitioner.

The DEA is authorized under federal law to pursue legal action in order to prevent the diversion of controlled substances and protect the public safety. A lack of compliance may result in a need for corrective action, such as administrative action (that is, Letter of Admonition, an informal hearing or "order to show cause"), or in extreme cases, civil, or criminal action.

\_\_\_\_\_

## **SECTION II – GENERAL REQUIREMENTS**

#### **Schedules of Controlled Substances**

The drugs and other substances that are considered controlled substances under the CSA are divided into five schedules. A complete list of the schedules is published annually on an updated basis in the DEA regulations, Title 21 of the Code of Federal Regulations, Sections 1308.11 through 1308.15. Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the United States and their relative abuse potential and likelihood of causing dependence when abused. Some examples of the drugs in each schedule are outlined below.

#### *IMPORTANT NOTE:*

All drugs listed in Schedule I have no currently accepted medical use in treatment in the United States and therefore may not be prescribed, administered, or dispensed for medical use. In contrast, drugs listed in Schedules II through V all have some accepted medical use and therefore may be prescribed, administered, or dispensed for medical use.

#### Schedule I Substances

Substances in this schedule have no currently accepted medical use in treatment in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.

Some examples of substances listed in Schedule I are: heroin; lysergic acid diethylamide (LSD); marijuana (cannabis); peyote; methaqualone; and methylene-dimethoxymethamphetamine ("ecstasy").

The CSA allows for bona fide research with controlled substances in Schedule I, provided that the FDA has determined the researcher to be qualified and competent, and provided further that the FDA has determined the research protocol to be meritorious. Researchers who meet these criteria must obtain a separate registration to conduct research with a Schedule I controlled substance.

#### **Schedule II Substances**

Substances in this schedule have a high potential for abuse with severe psychological or physical dependence.

Examples of single entity Schedule II narcotics include morphine, codeine, and opium. Other Schedule II narcotic substances and their common name brand products include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®), and fentanyl (Sublimaze® or Duragesic®).

-----

Examples of Schedule II stimulants include amphetamine (Dexedrine® or Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: cocaine, amobarbital, glutethimide, and pentobarbital.

#### **Schedule III Substances**

Substances in this schedule have a potential for abuse less than substances in Schedules I or II.

Examples of Schedule III narcotics include combination products containing less than 15 milligrams of hydrocodone per dosage unit (i.e., Vicodin®) and products containing not more than 90 milligrams of codeine per dosage unit (i.e., Tylenol with codeine®).

Examples of Schedule III non-narcotics include benzphetamine (Didrex®), phendimetrazine, dronabinol (Marinol®), ketamine, and anabolic steroids such as oxandrolone (Oxandrin®).

#### **Schedule IV Substances**

Substances in this schedule have a lower potential for abuse relative to substances in Schedule III.

Examples of a Schedule IV narcotics include propoxyphene (Darvon® and Darvocet-N 100®).

Other Schedule IV substances include alprazolam (Xanax®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).

#### Schedule V Substances

Substances in this schedule have a lower potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotic and stimulant drugs. These are generally used for antitussive, antidiarrheal and analgesic purposes.

Examples include cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, and Phenergan with Codeine®).

-----

### **Registration Requirements**

Under the CSA, the term "practitioner" is defined as a physician, dentist, veterinarian, scientific investigator, pharmacy, hospital, or other person licensed, registered, or otherwise permitted, by the United States or the jurisdiction in which the practitioner practices or performs research, to distribute, dispense, conduct research with respect to, administer, or use in teaching or chemical analysis, a controlled substance in the course of professional practice or research. Every person or entity that handles controlled substances <u>must</u> be registered with DEA or be exempt by regulation from registration.

The DEA registration grants practitioners federal authority to handle controlled substances. However, the DEA registered practitioner may only engage in those activities that are authorized under state law for the jurisdiction in which the practice is located. When federal law or regulations differ from state law or regulations, the practitioner is required to abide by the more stringent aspects of both the federal and state requirements. In many cases, state law is more stringent than federal law, and must be complied with in addition to federal law. Practitioners should be certain they understand their state as well as DEA controlled substance regulations.

### **Application for Registration**

To obtain a DEA registration, a practitioner must apply using a DEA Form 224. Applicants may submit the form by hard copy or on-line. Complete instructions accompany the form. To obtain the application, DEA may be contacted at:

- www.DEAdiversion.usdoj.gov (DEA Diversion Internet Web Site)
- any DEA field office (see listing in Appendix E of this manual)
- DEA Headquarters' Registration Section in Washington, D.C. at 1-800-882-9539 (Registration Call Center)

The DEA Form-224 may be completed on-line or in hard copy and mailed to:

Drug Enforcement Administration Registration Unit Central Station P.O. Box 28083 Washington, D.C. 20038-8083

A sample DEA Form 224 – New Application for Registration, is located at Appendix H, DEA Forms.

\_\_\_\_\_

### **Certificate of Registration**

The DEA Certificate of Registration (DEA Form 223) must be maintained at the registered location in a readily retrievable manner and kept available for official inspection.

The CSA requires that a separate registration be obtained for each principal place of business or professional practice where controlled substances are manufactured, distributed, or dispensed. DEA has historically provided an exception that a practitioner who is registered at one location, but also practices at other locations, is not required to register separately for any other location at which controlled substances are only prescribed. If the practitioner maintains supplies of controlled substances, administers, or directly dispenses controlled substances at the separate location the practitioner must obtain a separate DEA registration for that location. The exception applies only to a secondary location within the same state in which the practitioner maintains his/her registration. DEA individual practitioner registrations are based on state authority to dispense or conduct research with respect to controlled substances. Since a DEA registration is based on a state license, it cannot authorize controlled substance dispensing outside that state. Hence, the separate registration exception applies only to locations within the same state in which practitioners have their DEA registrations.

\_\_\_\_\_

A duplicate Certificate of Registration may be requested on-line. It appears on DEA's website, www.DEAdiversion.usdoj.gov, as follows:





### **Registration Renewals**

Practitioner registrations must be renewed every three years. Renewal registrations use DEA Form 224a, Renewal Application for DEA Registration (see example at Appendix H, DEA Forms). The cost of the registration is indicated on the application form.

A renewal application is sent to the registrant approximately 45 days before the registration expiration date. The renewal application is sent to the address listed on the current registration certificate. If the renewal form is not received within 30 days before the expiration date of the current registration, the practitioner should contact the DEA registration office for their state, or DEA Headquarters at 1-800-882-9539, and request a renewal registration form.

-----

The registration renewal application may be completed on-line at www.DEAdiversion.usdoj.gov, or in hard copy and mailed to:

Drug Enforcement Administration Registration Unit Central Station P.O. Box 28083 Washington, D.C. 20038-8083



Drug Registration > ODWIF

#### **Registration Applications**

#### Office of Diversion Control Web Interactive Forms (ODWIF)

#### RENEWAL APPLICATIONS

Log-in to Begin Renewal Process	Retail Pharmacy, Hospital/Clinic, Practitioner, Teaching Institution, or Mid-Level Practitioner, Manufacturer, Distributor, Researcher, Analytical Laboratory, Importer, Exporter, Domestic Chemicals
Obtain Receipt	This link may be used ONLY if you have previously submitted a Renewal Application through this tool and need an additional receipt.
<u>Duplicate</u> <u>Certificate</u>	On-line tool to request certificates for additional, misplaced, illegible, or destroyed originals.

#### MINIMUM ON-LINE REQUIREMENTS

The DEA Forms listed below are for those applying to DEA for a controlled substance registration. Data will be entered through a secure connection to the ODWIF on-line web application system. Your web browser must support 128-bit encryption.

You will need to have the following information handy in order to complete the form:

- Tax ID number and/or Social Security Number
- State Controlled Substance Registration Information
- State Medical License Information
- Credit Card (VISA, MasterCard, Discover or American Express)

The ODWIF system can only process credit card transactions at this time. If you are paying by check, you will need to  $\underline{\text{use the PDF version of the form}}$ , then print and mail the form to the address listed on the form.

-----

### **Change of Business Address**

A practitioner who moves to a new physical location must request a modification of registration. A modification of registration can be requested on-line at www.DEAdiversion.usdoj.gov or in writing to the DEA field office responsible for that state. If the change in address involves a change in state, the proper state issued license and controlled substances registration must be obtained prior to the approval of modification of the federal registration. If the modification is approved, DEA will issue a new certificate of registration and, if requested, new Schedule II order forms (DEA Form-222, Official Order Form). A Renewal Application for Registration (DEA Form-224a) will only be sent to the registered address on file with DEA. It will not be forwarded.

### **Termination of Registration**

Any practitioner desiring to discontinue business activities with respect to controlled substances must notify the nearest DEA field office (see Appendix E) in writing. Along with the notification of termination of registration, the practitioner should send the DEA Certificate of Registration and any unused Official Order Forms (DEA Form-222) to the nearest DEA field office.

### **Denial, Suspension or Revocation of Registration**

Under the CSA, DEA has the authority to deny, suspend, or revoke a DEA registration upon a finding that the registrant has:

- 1. Materially falsified any application filed
- 2. Been convicted of a felony relating to a controlled substance or a List I chemical
- 3. Had their state license or registration suspended, revoked, or denied
- 4. Committed an act which would render the DEA registration inconsistent with the public interest
- 5. Been excluded from participation in a Medicaid or Medicare program

In determining the public interest, the CSA states the following factors are to be considered:

- 1. The recommendation of the appropriate state licensing board or professional disciplinary authority
- 2. The applicant's experience in dispensing or conducting research with respect to controlled substances
- 3. The applicant's conviction record under federal or state laws relating to the manufacture, distribution, or dispensing of controlled substances
- 4. Compliance with applicable state, federal, or local laws relating to controlled substances
- 5. Such other conduct which may threaten the public health and safety

------

### Practitioner's Use of a Hospital's DEA Registration Number

Practitioners (e.g., intern, resident, staff physician, mid-level practitioner) who are agents or employees of a hospital or other institution may, when acting in the usual course of business or employment, administer, dispense, or prescribe controlled substances under the registration of the hospital or other institution in which they are employed, provided that:

- 1. The dispensing, administering, or prescribing is in the usual course of professional practice
- 2. Practitioners are authorized to do so by the state in which they practice
- 3. The hospital or institution has verified that the practitioner is permitted to dispense, administer or prescribe controlled substances within the state
- 4. The practitioner acts only within the scope of employment in the hospital or institution
- 5. The hospital or institution authorizes the practitioner to dispense or prescribe under its registration and assigns a specific internal code number for each practitioner so authorized (See example of a specific internal code number below):



A current list of internal codes and the corresponding individual practitioners is to be maintained by the hospital or other institution. This list is to be made available at all times to other registrants and law enforcement agencies upon request for the purpose of verifying the authority of the prescribing individual practitioner.

### **Inappropriate Use of the DEA Registration Number**

DEA strongly opposes the use of a DEA registration number for any purpose other than the one for which it was intended, to provide certification of DEA registration in transactions involving controlled substances. The use of DEA registration numbers as an identification number is not an appropriate use and could lead to a weakening of the registration system.

The Centers for Medicare and Medicaid Services has developed a National Provider Identification (NPI) number unique to each healthcare provider. The Final Rule for establishment of the NPI system was published in the Federal Register (FR 3434, Vol. 69, No. 15) by the Department of Health and Human Services on January 23, 2004. The effective date of this Final Rule was May 23, 2005; all covered entities must begin using the NPI in standard transactions by May 23, 2007.

\_\_\_\_\_\_

# **Exemption of Federal Government Practitioners from Registration**

The requirement of registration is waived for any official of the U.S. Army, Navy, Marine Corps, Air Force, Coast Guard, Public Health Service, or Bureau of Prisons who is authorized to prescribe, dispense, or administer, but not to procure or purchase controlled substances in the course of his/her official duties. Such officials shall follow procedures set forth in Title 21, CFR § 1306 regarding prescriptions, but shall state the branch of service or agency (e.g., "U.S. Army" or "Public Health Service") and the service identification number of the issuing official in lieu of the registration number required on prescription forms. The service identification number for a Public Health Service employee is his/her Social Security identification number.

If Federal Government practitioners wish to maintain a DEA registration for a private practice, which would include prescribing for private patients, they must be fully licensed to handle controlled substances by the state in which they are located. Under these circumstances, the Federal Government practitioner will not be eligible for the fee exemption and must pay a fee for the registration.

\_\_\_\_\_

## **SECTION III – SECURITY REQUIREMENTS**

### **Required Controls**

Title 21, CFR Section 1301.71(a), requires that all registrants provide effective controls and procedures to guard against theft and diversion of controlled substances. A list of factors is used to determine the adequacy of these security controls. Factors affecting practitioners include:

- 1. The location of the premises and the relationship such location bears on security needs
- 2. The type of building and office construction
- 3. The type and quantity of controlled substances stored on the premises
- 4. The type of storage medium (safe, vault, or steel cabinet)
- 5. The control of public access to the facility
- 6. The adequacy of registrant's monitoring system (alarms and detection systems)
- 7. The availability of local police protection

Practitioners are required to store stocks of Schedule II through V controlled substances in a securely locked, substantially constructed cabinet. Practitioners authorized to possess carfentanil, etorphine hydrochloride and/or diprenorphine, must store these controlled substances in a safe or steel cabinet equivalent to a U.S. Government Class V security container.

Registrants should not employ as an agent or employee who has access to controlled substances:

- 1. Any person who has been convicted of a felony offense related to controlled substances
- 2. Any person who has been denied a DEA registration
- 3. Any person who has had a DEA registration revoked
- 4. Any person who has surrendered a DEA registration for cause

Lastly, practitioners should notify the DEA, upon discovery, of any thefts or significant losses of controlled substances and complete a DEA Form 106 regarding such theft or loss.

-----

### **Safeguards for Prescribers**

In addition to the required security controls, practitioners can utilize additional measures to ensure security. These include:

- 1. Keep all prescription blanks in a safe place where they cannot be stolen; minimize the number of prescription pads in use.
- 2. Write out the actual amount prescribed in addition to giving a number to discourage alterations of the prescription order.
- 3. Use prescription blanks only for writing a prescription order and not for notes.
- 4. Never sign prescription blanks in advance.
- 5. Assist the pharmacist when they telephone to verify information about a prescription order; a corresponding responsibility rests with the pharmacist who dispenses the prescription order to ensure the accuracy of the prescription.
- 6. Contact the nearest DEA field office (see Appendix E) to obtain or to furnish information regarding suspicious prescription activities.
- 7. Use tamper-resistant prescription pads.

-----

# SECTION IV – RECORDKEEPING REQUIREMENTS

### **Recordkeeping Requirements**

Each practitioner must maintain inventories and records of controlled substances listed in Schedules I and II separately from all other records maintained by the registrant. Likewise, inventories and records of controlled substances in Schedules III, IV, and V must be maintained separately or in such a form that they are readily retrievable from the ordinary business records of the practitioner. All records related to controlled substances must be maintained and be available for inspection for a minimum of two years.

A registered practitioner is required to keep records of controlled substances that are dispensed to the patient, other than by prescribing or administering, in the lawful course of professional practice. A registered practitioner is not required to keep records of controlled substances that are prescribed in the lawful course of professional practice, unless such substances are prescribed in the course of maintenance or detoxification treatment. A registered practitioner is not required to keep records of controlled substances that are administered in the lawful course of professional practice unless the practitioner regularly engages in the dispensing or administering of controlled substances and charges patients, either separately or together with charges for other professional services, for substances so dispensed or administered. A registered practitioner is also required to keep records of controlled substances administered in the course of maintenance or detoxification treatment of an individual.

### **Inventory**

Each registrant who maintains an inventory of controlled substances must maintain a complete and accurate record of the controlled substances on hand and the date that the inventory was conducted. This record must be in written, typewritten, or printed form and be maintained at the registered location for at least two years from the date that the inventory was conducted. After an initial inventory is taken, the registrant shall take a new inventory of all controlled substances on hand at least every two years.

Each inventory must contain the following information:

- 1. Whether the inventory was taken at the beginning or close of business
- 2. Names of controlled substances
- 3. Each finished form of the substances (e.g., 100 milligram tablet)
- 4. The number of dosage units of each finished form in the commercial container (e.g., 100 tablet bottle)
- 5. The number of commercial containers of each finished form (e.g., four 100 tablet bottles)

\_\_\_\_\_

6. Disposition of the controlled substances

It is important to note that inventory requirements extend to controlled substance samples provided to practitioners by pharmaceutical companies.

### **Disposal of Controlled Substances**

A practitioner may dispose of out-of-date, damaged, or otherwise unusable or unwanted controlled substances, including samples, by transferring them to a registrant who is authorized to receive such materials. These registrants are referred to as "Reverse Distributors." The practitioner should contact the local DEA field office (See Appendix E) for a list of authorized Reverse Distributors. Schedule I and II controlled substances should be transferred via the DEA Form 222, while Schedule III–V compounds may be transferred via invoice. The practitioner should maintain copies of the records documenting the transfer and disposal of controlled substances for a period of two years.

\_\_\_\_\_\_

# SECTION V – VALID PRESCRIPTION REQUIREMENTS

### **Prescription Requirements**

A prescription is an order for medication which is dispensed to or for an ultimate user. A prescription is not an order for medication which is dispensed for immediate administration to the ultimate user (for example, an order to dispense a drug to an inpatient for immediate administration in a hospital is not a prescription).

A prescription for a controlled substance must be dated and signed on the date when issued. The prescription must include the patient's full name and address, and the practitioner's full name, address, and DEA registration number. The prescription must also include:

- 1. drug name
- 2. strength
- 3. dosage form
- 4. quantity prescribed
- 5. directions for use
- 6. number of refills (if any) authorized

A prescription for a controlled substance must be written in ink or indelible pencil or typewritten and must be manually signed by the practitioner on the date when issued. An individual (secretary or nurse) may be designated by the practitioner to prepare prescriptions for the practitioner's signature.

The practitioner is responsible for ensuring that the prescription conforms to all requirements of the law and regulations, both federal and state.

### Who May Issue

A prescription for a controlled substance may only be issued by a physician, dentist, podiatrist, veterinarian, mid-level practitioner, or other registered practitioner who is:

- 1. Authorized to prescribe controlled substances by the jurisdiction in which the practitioner is licensed to practice
- 2. Registered with DEA or exempted from registration (that is, Public Health Service, Federal Bureau of Prisons, or military practitioners)
- 3. An agent or employee of a hospital or other institution acting in the normal course of business or employment under the registration of the hospital or other institution which is registered in lieu of the individual practitioner being registered provided that additional requirements as set forth in the CFR are met.

\_\_\_\_\_

### **Purpose of Issue**

To be valid, a prescription for a controlled substance must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. The practitioner is responsible for the proper prescribing and dispensing of controlled substances. In addition, a corresponding responsibility rests with the pharmacist who fills the prescription. An order purporting to be a prescription issued not in the usual course of professional treatment or in legitimate and authorized research is not a valid prescription within the meaning and intent of the Controlled Substances Act and the person knowingly filling such a purported prescription, as well as the person issuing it, shall be subject to the penalties provided for violations of the provisions of law relating to controlled substances.

A prescription may not be issued in order for an individual practitioner to obtain controlled substances for supplying the individual practitioner for the purpose of general dispensing to patients.

#### Schedule II Substances

Schedule II controlled substances require a written prescription which must be signed by the practitioner. There is no federal time limit within which a Schedule II prescription must be filled after being signed by the practitioner.

While some states and many insurance carriers limit the quantity of controlled substance dispensed to a 30-day supply, there are no specific federal limits to quantities of drugs dispensed via a prescription. For Schedule II controlled substances, an oral order is only permitted in an emergency situation.

#### **Refills**

The refilling of a prescription for a controlled substance listed in Schedule II is prohibited (Title 21 U.S. Code § 829(a)).

### **Issuance of Multiple Prescriptions for Schedule II Substances**

DEA has revised its regulations regarding the issuance of multiple prescriptions for schedule II controlled substances. Under the new regulation, which became effective December 19, 2007, an individual practitioner may issue multiple prescriptions authorizing the patient to receive a total of up to a 90-day supply of a schedule II controlled substance provided the following conditions are met:

1. Each separate prescription is issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice.

- 2. The individual practitioner provides written instructions on each prescription (other than the first prescription, if the prescribing practitioner intends for that prescription to be filled immediately) indicating the earliest date on which a pharmacy may fill each prescription.
- 3. The individual practitioner concludes that providing the patient with multiple prescriptions in this manner does not create an undue risk of diversion or abuse.
- 4. The issuance of multiple prescriptions is permissible under applicable state laws.
- 5. The individual practitioner complies fully with all other applicable requirements under the Controlled Substances Act and Code of Federal Regulations, as well as any additional requirements under state law.

It should be noted that the implementation of this change in the regulation should not be construed as encouraging individual practitioners to issue multiple prescriptions or to see their patients only once every 90 days when prescribing schedule II controlled substances. Rather, individual practitioners must determine on their own, based on sound medical judgment, and in accordance with established medical standards, whether it is appropriate to issue multiple prescriptions and how often to see their patients when doing so.

# Facsimile Prescriptions for Schedule II Controlled Substances

In order to expedite the filling of a prescription, a prescriber may transmit a Schedule II prescription to the pharmacy by facsimile. The original Schedule II prescription must be presented to the pharmacist for review prior to the actual dispensing of the controlled substance.

In an emergency, a practitioner may call-in a prescription for a Schedule II controlled substance by telephone to the pharmacy, and the pharmacist may dispense the prescription provided that the quantity prescribed and dispensed is limited to the amount adequate to treat the patient during the emergency period. The prescribing practitioner must provide a written and signed prescription to the pharmacist within seven days. Further, the pharmacist must notify DEA if the prescription is not received.

\_\_\_\_\_

### **Exceptions for Schedule II Facsimile Prescriptions**

DEA has granted three exceptions to the facsimile prescription requirements for Schedule II controlled substances. The facsimile of a Schedule II prescription may serve as the original prescription as follows:

- 1. A practitioner prescribing Schedule II narcotic controlled substances to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, subcutaneous or intraspinal infusion may transmit the prescription by facsimile. The pharmacy will consider the facsimile prescription a "written prescription" and no further prescription verification is required. All normal requirements of a legal prescription must be followed.
- 2. Practitioners prescribing Schedule II controlled substances for residents of Long Term Care Facilities (LTCF) may transmit a prescription by facsimile to the dispensing pharmacy. The practitioner's agent may also transmit the prescription to the pharmacy. The facsimile prescription serves as the original written prescription for the pharmacy.
- 3. A practitioner prescribing a Schedule II narcotic controlled substance for a patient enrolled in a hospice care program certified and/or paid for by Medicare under Title XVIII or a hospice program which is licensed by the state may transmit a prescription to the dispensing pharmacy by facsimile. The practitioner or the practitioner's agent may transmit the prescription to the pharmacy. The practitioner or agent will note on the prescription that it is for a hospice patient. The facsimile serves as the original written prescription.

#### **Schedule III-V Substances**

A prescription for controlled substances in Schedules III, IV, and V issued by a practitioner, may be communicated either orally, in writing, or by facsimile to the pharmacist, and may be refilled if so authorized on the prescription or by call-in.

#### Refills

Schedule III and IV controlled substances may be refilled if authorized on the prescription. However, the prescription may only be refilled up to five times within six months after the date on which the prescription was issued. After five refills or after six months, whichever occurs first, a new prescription is required.

\_\_\_\_\_

### **Facsimile Prescriptions for Schedule III-V Substances**

Prescriptions for Schedules III-V controlled substances may be transmitted by facsimile from the practitioner or an employee or agent of the individual practitioner to the dispensing pharmacy. The facsimile is considered to be equivalent to an original prescription.

### **Telephone Authorization for Schedule III-V Prescriptions**

A pharmacist may dispense a controlled substance listed in Schedule III, IV, or V pursuant to an oral prescription made by an individual practitioner and promptly reduced to writing by the pharmacist containing all information required for a valid prescription, except for the signature of the practitioner.

### Delivery of a Controlled Substance to Persons Outside the U.S.

Controlled substances that are dispensed pursuant to a legitimate prescription may not be delivered or shipped to individuals in another country. Any such delivery or shipment is a prohibited export under the CSA.

-----

# SECTION VI – OPIOID (NARCOTIC) ADDICTION TREATMENT PROGRAMS

The Narcotic Addiction Treatment Act of 1974 and the Drug Addiction Treatment Act of 2000 amended the CSA with respect to the use of controlled substances in the medical treatment of addiction. These laws established the procedures for approval and licensing of practitioners involved in the treatment of opioid addiction as well as improving the quality and delivery of that treatment to the segment of society in need.

Practitioners wishing to administer and dispense approved Schedule II controlled substances (that is, methadone) for maintenance and detoxification treatment must obtain a separate DEA registration as a Narcotic Treatment Program. Application for registration as a Narcotic Treatment Program is made using DEA Form 363. In addition to obtaining this separate DEA registration, this type of activity also requires the approval and registration of the Center for Substance Abuse Treatment (CSAT) within the Substance Abuse and Mental Health Services Administration (SAMHSA) of the Department of Health and Human Services (HHS), as well as the applicable state methadone authority.

If a practitioner wishes to prescribe, administer, or dispense Schedule III, IV, or V controlled substances approved for addiction treatment (i.e., buprenorphine drug products), the practitioner must request a waiver (Form SMA-167) and fulfill the requirements of CSAT. CSAT will then notify DEA of all waiver requests. DEA will review each request. If DEA approves this waiver, the practitioner will receive a Unique Identification Number. If a practitioner chooses to dispense controlled substances, the practitioner must maintain, separate from all other records, for a period of at least two years, all required records of receipt, storage, and distribution. If a practitioner chooses to prescribe these controlled substances, the practitioner must utilize their Unique Identification Number on the prescription in addition to his/her regular DEA registration number. The practitioner must also maintain a record of each such prescription for a period of at least two years. Practitioners should be aware that there may be limits on how many patients they may treat for opioid addiction at any given time and should check with SAMHSA to determine these limits.

Note that not all treatment programs utilize controlled substances, that is, some are drug free. Accordingly, these activities do not require DEA registration or approval.

Practitioners can find additional information regarding addiction treatment by visiting DEA's Office of Diversion Control website at www.DEAdiversion.usdoj.gov. Click on "Publications," then "Narcotic Treatment Programs: Best Practices Guidelines." The DEA application Form 363 may be completed on-line.

To learn more about CSAT's requirements, practitioners may visit one or more of the following websites: <a href="www.samhsa.gov/centers/csat2002/csat\_frame.html">www.samhsa.gov/centers/csat2002/csat\_frame.html</a>, www.csat.samhsa.gov, or <a href="www.buprenorphine.samhsa.gov">www.buprenorphine.samhsa.gov</a>.

If the practitioner has a patient who is in need of addiction treatment, but does not wish to treat the individual, the practitioner can refer the patient to an existing facility through the following website: <a href="www.findtreatment.samhsa.gov">www.findtreatment.samhsa.gov</a>.

-----

# **APPENDICES**

\_\_\_\_\_

### **APPENDIX A**

### **CSA & CFR Definitions**

#### Administer

The direct application of a controlled substance to the body of a patient or research subject by 1) a practitioner or (in his presence) by his authorized agent, or 2) the patient or research subject at the direction and in the presence of the practitioner, whether such application is by injection, inhalation, ingestion, or any other means.

#### **Dispense**

To deliver a controlled substance to an ultimate user or research subject by, or pursuant to the lawful order of, a practitioner, including the prescribing and administering of a controlled substance and the packaging, labeling, or compounding necessary to prepare the substance for such delivery.

#### Dispenser

An individual practitioner, institutional practitioner, pharmacy or, pharmacist who dispenses a controlled substance.

#### **Individual Practitioner**

A physician, dentist, veterinarian, or other individual licensed, registered or otherwise permitted, by the United States or the jurisdiction in which they practice, to dispense a controlled substance in the course of professional practice, but does not include a pharmacist, a pharmacy, or an institutional practitioner.

#### **Institutional Practitioner**

A hospital or other person (other than an individual) licensed, registered or otherwise permitted, by the United States or the jurisdiction in which it practices, to dispense a controlled substance in the course of professional practice, but does not include a pharmacy.

#### **Inventory**

All factory and branch stocks in finished form of a basic class of controlled substance manufactured or otherwise acquired by a registrant, whether in bulk, commercial containers, or contained in pharmaceutical preparations in the possession of the registrant (including stocks held by the registrant under separate registration as a manufacturer, importer, exporter, or distributor).

-----

#### **Long Term Care Facility**

A nursing home, retirement care, mental care, or other facility or institution which provides extended health care to resident patients.

#### **Mid-level Practitioner**

An individual practitioner, other than a physician, dentist, veterinarian, or podiatrist, who is licensed, registered or otherwise permitted by the United States or the jurisdiction in which he/she practices, to dispense a controlled substance in the course of professional practice. Examples of mid-level practitioners include, but are not limited to, health care providers such as nurse practitioners, nurse midwives, nurse anesthetists, clinical nurse specialists, and physician assistants who are authorized to dispense controlled substances by the state in which they practice.

#### **Pharmacist**

Any pharmacist licensed by a state to dispense controlled substances, and shall include any other person (e.g., pharmacist intern) authorized by a state to dispense controlled substances under the supervision of a pharmacist licensed by such state.

#### Prescription

An order for medication which is dispensed to or for an ultimate user but does not include an order for medication which is dispensed for immediate administration to the ultimate user (e.g., an order to dispense a drug to a bed patient for immediate administration in a hospital is not a prescription).

#### **Readily Retrievable**

Certain records are kept by automatic data processing systems or other electronic or mechanized record keeping systems in such a manner that they can be separated out from all other records in a reasonable time and/or records are kept on which certain items are asterisked, redlined, or in some other manner visually identifiable apart from other items appearing on the records.

#### -----

### **APPENDIX B**

### **Questions and Answers**

The following questions are those that are frequently encountered by DEA's Office of Diversion Control and its field units. These questions and their accompanying answers are provided in context of the CSA and its federal regulations.

# **Q** Are separate registrations required for separate locations?

**A** A separate registration is required for each principal place of business or professional practice where controlled substances are stored or dispensed by a person.

# Q Does a practitioner need a separate registration to treat patients at remote health care facilities?

A Separate registration is not required in an office used by a practitioner (who is registered at another location) where controlled substances are prescribed but neither administered nor otherwise dispensed as a regular part of the professional practice of the practitioner at such office, and where no supplies of controlled substances are maintained.

## Q Do all practitioners in a group practice need to be registered?

A An individual practitioner who is an agent or employee of another practitioner (other than a mid-level practitioner) registered to dispense controlled substances may, when acting in the normal course of business or employment, administer or dispense (other than by issuance of prescription) controlled substances if and to the extent that such individual practitioner is authorized or permitted to do so by the jurisdiction in which he or she practices, under the registration of the employer or principal practitioner in lieu of being registered him/herself.

## ${f Q}$ Do medical residents assigned to hospitals need to register?

A An individual practitioner who is an agent or employee of a hospital or other institution may, when acting in the normal course of business or employment, administer, dispense, or prescribe controlled substances under the registration of the hospital or other institution which is registered in lieu of being registered provided that additional requirements as set forth in the CFR are met.

### O Are military personnel exempted from registration?

A Registration is waived for any official of the U.S. Army, Navy, Marine Corps, Air Force, or Coast Guard who is authorized to prescribe, dispense, or administer, but not procure or purchase, controlled substances in the course of his/her official duties. Such officials must follow procedures set forth in 21 CFR Part 1306 regarding prescriptions. Branch of service or agency and the service identification number of the issuing official is required on the prescription form in lieu of the DEA registration number.

If any exempted official engages as a private individual in any activity or group of activities for which registration is required, that individual must obtain a registration for those private activities.

Further, practitioners serving in the U.S. Military are exempt from registering with DEA, but are not authorized to procure or purchase controlled substances in the course of their official duties.

A number of states also require military practitioners to acquire a separate state license if they issue prescriptions that are filled outside the military facility where they practice.

# Q Are contract practitioners working at U.S. Military Installations also exempt from registration?

A They are not exempt. A contract practitioner who is not an official of the military on active duty, but is engaged in medical practice at a military installation, must possess a current DEA registration. The individual must also possess a valid state license for the same state in which he/she is registered with DEA.

### Q What should a practitioner do if he/she discovers a theft or loss?

A Registrants must notify the DEA field office in their area of the theft or significant loss of any controlled substances upon discovery. The registrant must also complete DEA Form 106 documenting the loss or theft.

\_\_\_\_\_\_

# ${f Q}$ What is meant by "acceptable medical practice?"

A The legal standard that a controlled substance may only be prescribed, administered, or dispensed for a legitimate medical purpose by a physician acting in the usual course of professional practice has been construed to mean that the prescription must be "in accordance with a standard of medical practice generally recognized and accepted in the United States"

Federal courts have long recognized that it is not possible to expand on the phrase "legitimate medical purpose in the usual course of professional practice" in a way that will provide definitive guidelines to address all the varied situations physicians may encounter.

While there are no criteria to address every conceivable instance of prescribing, there are recurring patterns that may be indicative of inappropriate prescribing:

- An inordinately large quantity of controlled substances prescribed or large numbers of prescriptions issued compared to other physicians in an area;
- No physical examination was given;
- Warnings to the patient to fill prescriptions at different drug stores;
- Issuing prescriptions knowing that the patient was delivering the drugs to others;
- Issuing prescriptions in exchange for sexual favors or for money;
- Prescribing of controlled drugs at intervals inconsistent with legitimate medical treatment;
- The use of street slang rather than medical terminology for the drugs prescribed; or
- No logical relationship between the drugs prescribed and treatment of the condition allegedly existing.

Each case must be evaluated based on its own merits in view of the totality of circumstances particular to the physician and patient.

For example, what constitutes "an inordinately large quantity of controlled substances," can vary greatly from patient to patient. A particular quantity of a powerful Schedule II opioid might be blatantly excessive for the treatment of a particular patient's mild temporary pain, yet insufficient to treat the severe unremitting pain of a cancer patient.

### Q What information is required to be provided on a written prescription?

A All written prescriptions for controlled substances must be dated as of, and signed on, the date when issued. Each prescription must indicate the full name and address of the patient, the drug name, strength, dosage form, quantity prescribed,

directions for use and the name, address, and DEA number of the practitioner. Further, prescriptions must be written in ink, indelible pencil, or by typewriter, and must be manually signed by the practitioner.

### Q What is meant by "date of issuance?"

A The date a prescription is issued is the same date that the prescribing practitioner actually writes and signs the prescription.

## **Q** Is there a time limit for filling Schedule II prescriptions?

**A** There is no federal time limit for filling Schedule II prescriptions. However, some state laws do set time limits.

\_\_\_\_\_

### **APPENDIX C**

## Summary of Controlled Substances Act Requirements

	Schedule II	Schedule III & IV	Schedule V
Registration	Required	Required	Required
Receiving Records	Order Forms (DEA Form-222)	Invoices, Readily Retrievable	Invoices, Readily Retrievable
Prescriptions	Written Prescription (See exceptions*)	Written, Oral, or Fax	Written, Oral, Fax, or Over The Counter**
Refills	No	No more than 5 within 6 months	As authorized when prescription is issued
Distribution Between Registrants	Order Forms (DEA Form-222)	Invoices	Invoices
Security	Locked Cabinet or Other Secure Storage	Locked Cabinet or Other Secure Storage	Locked Cabinet or Other Secure Storage
Theft or Significant Loss	Report and complete DEA Form 106	Report and complete DEA Form 106	Report and complete DEA Form 106

Note: All records must be maintained for 2 years, unless a state requires a longer period.

<sup>\*</sup> Emergency prescriptions require a signed follow-up prescription.

Exceptions: A facsimile prescription serves as the original prescription when issued to residents of Long Term Care Facilities, Hospice patients, or compounded IV narcotic medications.

<sup>\*\*</sup> Where authorized by state controlled substances authority.

#### \_\_\_\_\_

### APPENDIX D

## **Internet Resources**

### <u>DEA's Diversion Control Program Website</u> www.DEAdiversion.usdoj.gov

### **DEA Homepage**

www.dea.gov

### **U.S. Government Printing Office**

www.gpoaccess.gov/cfr/index.html

Provides access to the Code of Federal Regulations (21 CFR, Parts 1300 to end), primary source for the Practitioner's Manual, and the Federal Register which contains proposed and finalized amendments to the CFR.

### Office of National Drug Control Policy (ONDCP)

www.whitehousedrugpolicy.gov

### **Food and Drug Administration**

www.FDA.gov

## **HHS & SAMHSA's National Clearinghouse for Alcohol and Drug**

## <u>Information</u>

www.health.org

## SAMHSA/CSAT

www.csat.samhsa.gov

### **Federation of State Medical Boards**

www.FSMB.org

## National Association of Boards of Pharmacy

www.nabp.net

## **National Association of State Controlled Substances Authorities**

www.nascsa.org

\_\_\_\_\_

## **APPENDIX E**

## **Drug Enforcement Administration Diversion Field Office Locations**

For address and telephone number updates, please see the DEA website: www.deadiversion.usdoj.gov/offices n dirs/index.html

Appendix E pages 34-39 of this manual contained outdated Field Office Information and therefore have been removed. Please refer to the above link for current Diversion Field Office Locations.

\_\_\_\_\_

## **APPENDIX F**

## Small Business and Agriculture Regulatory Enforcement Ombudsman

The Small Business and Agriculture Regulatory Enforcement Ombudsman and 10 Regional Fairness Boards were established to receive comments from small businesses about federal agency enforcement actions. The Ombudsman will annually evaluate the enforcement activities and rate each agency's responsiveness to small business. If you wish to comment on DEA enforcement actions, you may contact the Ombudsman at 1-888-REG-FAIR (1-888-734-3247).

\_\_\_\_\_

## APPENDIX G

### **Additional Assistance**

This publication is intended to provide guidance and information on the requirements of the Controlled Substances Act and its implementing regulations. If you require additional clarification or assistance, or wish to comment on any matter regarding the DEA's requirements or regulatory activities, please contact your local DEA Diversion field office (see Appendix E). Every effort will be made to respond promptly to your inquiry.

## Plain Language

The Drug Enforcement Administration has made every effort to write this manual in clear, plain language. If you have suggestions as to how to improve the clarity of this manual, please contact us at:

Drug Enforcement Administration Office of Diversion Control Liaison and Policy Section Washington, D.C. 20537 Telephone: (202) 307-7297

\_\_\_\_\_

## APPENDIX H – DEA FORMS

The following pages provide samples of several forms frequently encountered by DEA registrants. Included are:

DEA Form 41	Registrants Inventory of Drugs Surrendered
DEA Form 106	Report of Theft or Loss of Controlled Substances
DEA Form 222	U.S. Official Order Form for Controlled Substances
DEA Form 224	Application for Registration
DEA Form 224a	Renewal Application for DEA Registration
DEA Form 363	Application for Registration as a Narcotic Treatment Program
DEA Form 363a	Renewal Application for DEA Registration as a Narcotic Treatment Program

	Department of Justice / Drug Enfor					ACKAGE NO	
The following schedule is an for proper disposition.	-	ubstance	s which	is hereby	y surrendere	d to you	
FROM: (Include Name, Street, City, State and Zi	P Code in space provided below.)						
_	-	⊣		Signature o	fapplicant or au	thorized ager	rt.
'		•					
ı				Registrant	s DEA Number		
L	-	_		Registrant	s Telephone Num	ber	
NOTE: CERTIFIED MAIL (Return Receipt Requi OF DRUGS VIA U.S. POSTAL SERVICE	ested) IS REQUIRED FOR SHIPM E. See instructions on reverse (pag	ENTS pe 2) of form	1.				
NAME OF DRUG OR PRE	PARATION	Number	(Number of grams, tablets,	of trolled Sub- stance	FOR D	EA USE O	NLY
		Con- tainers	ounces o other unit per con-	s tent,	DISPOSITIO	N QUA	NTITY
Registrants will fill in Columns 1	,2,3, and 4 ONLY.		tainer)	Unit)		GMS.	MGS.
1		2	3	4	5	6	7
2							
3							
4							
5							
6						+	
7						+	
8							
9							
10							
12							
13							
14							
15							
16 FORM DEA-41 (9-01)	Previous edition dated 6-86 is us			2000	ictions on reverse		

DEA-41 (6/1986) Pr. 2

NAME OF DRUG OR PREPARATION	Number	CONTENTS (Number of grams, tablets,	Con- trolled Sub- stance	FOR DEA USE ONLY			
	Con- tainers	ounces or other units per con-	Con- tent, Œach		DISPOSITION	QUANTITY	
Registrants will fill in Columns 1,2,3, and 4 ONLY.		tainer)	Unit)		GMS.	MGS.	
17	2	3	4	5	6	7	
18							
19							
20							
21							
22							
23							
24							
The controlled substances surrendered in accordance with Title 21 of inpackages purporting to contain the drugs listed on this invent (2) Destroyed as indicated and the remainder forwarded tape-sealed after the controlled tape-sealed	ory and have been: "	" (1) Forwarde	d tape-se	ealed without openin	g;		
DATE	DESTROYED BY:					_	
" Stilke out lines not applicable.	WITNESSED BY:					_	

#### INSTRUCTIONS

- 1. List the name of the drug in column 1, the number of coutsiners in column 2, the size of each container in column 3, and in column 4 the commolled substance content of each unit described in column 3; e.g., morphine sulfate tabs., 3 pags., 100 tabs., 1/4 gr. (16 mg.) or morphine sulfate tabs., 1 pag., 83 tabs., 1/2 gr. (32 mg.), etc.
- 2. All packages included on a single line should be identical in name, content and controlled substance strength.
- 3. Prepare this form in quadruplicate. Mail two (2) copies of this form to the Special Agent in Charge, under separate cover. Enclose one additional copy in the shipment with the drugs. Retain one copy for your records. One copy will be returned to you as a receipt. No further receipt will be furnished to you unless specifically requested. Any further inquiries concerning these drugs should be addressed to the DEA District Office which serves your area.
- 4. There is no provision for payment for drugs surrendered. This is merely a service rendered to registrants enabling them to clear their stocks and records of unwanted items
- Drugs should be shipped tope-scaled via prepaid express or certified mail (return receipt requested) to Special Agent in Charge, Drug Enforcement Administration, of the DEA District Office which serves your area.

#### PRIVACY ACT INFORMATION

AUTHORITY: Section 307 of the Controlled Substances Act of 1970 (PL 91-513).

PURPOSE: To document the surrender of controlled substances which have been forwarded by registrants to DEA for disposal.

ROUTINE USES: This form is required by Federal Regulations for the surrender of unwarded Controlled Substances. Disclosures of information from this system are made to the following categories of uses for the purposes stated.

A. Other Federal law enforcement and regulatory agencies for law enforcement and regulatory purposes.

B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes.

EFFECT: Failure to document the surrender of unwanted Controlled Substances may result in prosecution for violation of the Controlled Substances Act.

Under the Paperwork Reduction Act, a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Drug Enforcement Administration, FOI and Records Management Section, Washington, D.C. 20537; and to the Office of Management and Budget, Paperwork Reduction Project no. 1117-0007, Washington, D.C. 20503.



REPO	RT OF THEFT OR LOSS (	OF CONTROLLED	SUBSTANCES	
Federal Regulations require registrants to	submit a detailed report of any theft or	loss of Controlled Substance	es to the Drug	
Enforcement Administration.  Complete the front and back of this form	in triplicate. Forward the original and o	Suplicate copies to the near	OMB APPROV est DEA Office. No. 1117-0001	
Retain the triplicate copy for your records  1. Name and Address of Registrant (include		of this report.		
1. Name and Address of Registrant (include	zir code)	ZIP CODE	2. Phone No. (Include Area Code	•)
			1	
			]	
3. DEA Registration Number	4. Date of Theft or Loss	5. Principal Business of 8	Registrant (Check one)	
2 ltr. prefix 7 digit suffix	<del>, , ,</del>	1 Pharmacy	5 Distributor	
		2 ☐ Practitioner 3 ☐ Manufacture	6 ☐ Methadone Progra r 7 ☐ Other (Specify)	m
		4 Hospital/Clir	(-p//	
		ephone Number of Police Dep	artment (Include Area Code)	
located to F	Police?			
	Yes No			
9. Number of Thefts or Losses Registrant	10. Type of Theft or Loss (Check one	and complete items below:	e appropriate)	
has experienced in the past 24 months				
		mployee pilferage	5 Other (Explain)	445
	2 ∐ Armed robbery 4 ☐ 0	Sustomer theft	6 Lost in transit (Complete Item	n 14)
11. If Armed Robbery, was anyone:	12. Purchase value Controlled Sub	e to registrant of stances taken?	<ol><li>Were any pharmaceuticals or merchandise taken?</li></ol>	
Killed? ☐ No ☐ Yes (How many) _			No Yes (Est. Value)	
Injured? No Yes (How many)	\$		\$	
14. IF LOST IN TRANSIT, COMPLETE THE	FOLLOWING:	I		
A. Name of Common Carrier	B. Name of Consignee	C	. Consignee's DEA Registration Num	iber
D. Was the carton received by the customer	? E. If received, did it appear to	be tampered with?	Have you experienced losses in trans	sit
			from this same carrier in the past?	
∐ Yes ∐ No	Yes	No	□ No □ Yes (How Many) _	
<ol><li>What identifying marks, symbols, or price</li></ol>	e codes were on the labels of these co	ntainers that would assist in	identifying the products?	
16. If Official Controlled Substance Order F	orms (DEA-222) were stolen, give num	bers.		
17. What security measures have been tak	en to prevent future thefts or losses?			
PRIVACYACTINE	ORMATION	In accordance with the Pa	perwork Reduction Act of 1995, no	person is
AUTHORITY: Section 301 of the Controlled S	ubstances Act of 1970 (PL 91-513).		blection of information unless it dis r. The valid OMB control number for	
PURPOSE: Report theft or loss of Controlled ROUTINE USES: The Controlled Substances	Substances.	collection of information is	1117-0001. Public reporting burden f	or this
special reports required for statistical and a	nalytical purposes. Disclosures of	response, including the t	s estimated to average 30 minutes p ime for reviewing instructions, searc	ching
information from this system are made to the purposes stated:	e following categories of users for the	existing data sources, gar completing and reviewing	thering and maintaining the data ne- the collection of information.	eded, and
A. Other Federal law enforcement and regu	latory agencies for law enforcement	completing that reviewing	are concentrated an intermediated.	
and regulatory purposes.  B. State and local law enforcement and reg	ulatory agencies for law enforcement			
and regulatory purposes.				
EFFECT: Failure to report theft or loss of cont penalties under Section 402 and 403 of				
FORM DEA . 400 (44.00) D			CONTINUE ON D	D/FDOF

Trade Nan	ne of Substance or Preparation	Name of Controlled Substance in Preparation	Dosage Strength and Form	Quantity
xamples:	Desoxyn	Methamphetamine Hydrochloride	5 mg Tablets	3 x 100
	Demerol	Meperidine Hydrochloride	50 mg/ml Vial	5 x 30 ml
	Robitussin A-C	Codeine Phosphate	2 mg/cc Liquid	12 Pints
). I.				
ł				
i.				
ì.				
0.				
1.				
2.				
3. 4.				-
4. 5.				
6.				-
				-
7. 8.				-
o. 9.				
20.				
21.				
2.				
23. 24.				
				-
25.				
26. 27.				
28.				
20.				
				-
0.				-
1. 2.				
3.				
4.				
15.				
16. 37.				
38.				-
19.				-
				-
0.				-
1.				-
2.				-
13.				-
4.				-
5. 6.				-
t. 7.				-
				-
8. 9.				-
9. 0.				-
w.				
	I certify that the	foregoing information is correct to the best of n	ny knowledge and belief.	
Signature		Title	Date	

\_\_\_\_\_

## DEPICTION of PAGE 1 of DEA FORM-222 U.S. OFFICIAL ORDER FORM - SCHEDULES I & II

Se		of PURCHAS								OMB APPROVAL No. 1117-0010							
TO:	(Name of Su	pplier)	·			STREET	ADI	DRE	SS								
CIT	Y and STAT	E		DATE		!				то	BE F	FILL	.ED	IN E	Y S	UPPLIER	
							SU	PPL	JER	S DE	A R	EGI	STF	RATI	ON	No.	
L		TO BE FII	LED IN BY	PURCHAS	ER												
I N E No.	No. of Packages	Size of Package		Name of	ltem				Nati	onal	Dru	g Co	ode			Packages Shipped	Date Shipped
1																	
2																	
3																	
4																	
5																	
6																	
7																	
8																	
9																	
10																	
		LAST LINE COMPLETED	) (MUST	BE 10 OR L		GNATURE R ATTORI					ER						•
Dat	e Issued		DEA Regis	stration No.	Name	and Addre	ess o	of R	egis	trant							
Sch	nedules																
Reg	gistered as a		No. of this	Order Form													

DEA Form-222 (Oct. 1992) U.S. OFFICIAL ORDER FORMS - SCHEDULES I & II

DRUG ENFORCEMENT ADMINISTRATION

SUPPLIER'S Copy 1

Note: The graphic illustrated above is not intended to be used as an actual order form.

Form-224	APPLICATION FOR REGISTRATION Under the Controlled Substances Act	APPROVED OMB NO 1117-00 FORM DEA-224 (9-0 Previous editions are obsole
INSTRUCTIONS	1. To apply by mail complete this application. Keep a copy for your records. 2. Print cleant, using black or blue ink, or use a typewriter. 3. Mail this form to the address provided in Section 7 or use enclosed envelope. 4. Include the correct payment amount. FEE IS NON-REFUNDABLE. 5. If you have any questions call 600-602-9030 prior to submitting your application. 6. Save time - apply online at www.deadiversion.usdoj.gov.	REGISTRATION INFORMATION:
	IMPORTANT: DO NOT SEND THIS APPLICATION AND APPLY ONLINE.	_
		\$390.00
		FEE IS NON-REFUNDABLE
SECTION 1 API	PLICANT NTIFICATION	
Last Name (if regi	stration is for individual) -OR- Business or Facility Name (if registration is for bu	siness entity)
First Name (If regi	stration is for individual)	Middle Initial
Business or Facili	ly Name 2 ("doing business as", continuation of business name, or name of fee exempt in	stitution)
Address Line 1 (st	reet address)	
Address Line 2		
City		State Zip Code
Business Phone N	lumber Business Fax Number	
DEBT COLLECTION INFORMATION	Tax Identification Number (Fregistration is for business) Social Se	ecurity Number (if registration is for individual)
Mandatory pursuant to Debt Collection Improvements Act		Provide SSN or TIP See note #3 on bottom of page 2
SECTION 2 BUSINESS ACTIVITY	☐ Hospital/Clinic ☐ Ambulance Service ☐ Practitions, in	oner DMD, DO, DPM, DVM, MD or PHD) PROFESSIONAL DEGREE
Check one box only	□ Nursing Home □ Animal Shelter □ Practit (DDS, I	ioner Military Practitioners and MLP: DMD, DO, DPM, DVM,MD or PHD) Enter your professions degree from list
See page 3 for additional instructions	☐ Central Fill Pharmacy ☐ Teaching Institution ☐ Mid-le (DCM,	vel Practitioner (MLP) HMD, MP, ND, NP, OD, PA, or RPH)
	Retail Pharmacy Automated Dispensing System Euthan	nasia Technician
FOR Automated Dispension (ADS) ONLY:	ng System DEA Registration # of Retail Pharmacy for this ADS	An ADS is automatically fee-exempt. Skip Section 6 and Section 7 on page 2. You must attach a notorized affidavit.
SECTION 3	Schedule II Narcotic Schedule III Narcotic	☐ Schedule IV
DRUG SCHEDULES	Schedule II Non-Narcotic Schedule III Non-Narcotic	Schedule V
Check all that apply	Check this box if you require official order forms for purchase of	
	schedule II narcotic/schedule II non-narcotic controlled substances	

SECTION 4	Are you currently authorized to prescribe, distribute, dispense, conduct research, or otherwis the schedules for which you are applying under the laws of the state or jurisdiction in which y	se handle the controlled substances in
STATE LICENSE(S)	YES PENDING NO	State
Be sure to include both state license numbers if applicable		License Number
- прриоды		State Controlled Substance License Number (If required)
SECTION 5	<ol> <li>Has the applicant ever been convicted of a crime in connection with controlled substance(s)</li> </ol>	s) under state or federal law?
IMPORTANT	2. Has the applicant ever surrendered (for cause) or had a federal controlled substance registrestricted, or denied?	ation revoked, suspended,
this section must	<ol><li>Has the applicant ever surrendered (for cause) or had a state professional license or control revoked, suspended, denied, restricted, or placed on probation? Is any such action pendir</li></ol>	lled substance registration
be answered.	4. If the applicant is a corporation (other than a corporation whose stock is owned and traded partnership, or pharmacy, has any officer, partner, stockholder, or proprietor been convicted controlled substance(s) funder state or rederal law, or ever surrendered, for cause, or had a f registration revoked, suspended, restricted, denied, or ever had a state professional license registration revoked, suspended, denied, restricted or placed on probation?	by the public), association, of a crime in connection with dederal controlled substance or controlled substance
EXPLANATION OF "YES" ANSWERS	Date(s) of incident: Location(s) of incident:	
Applicants who have answered "YES" to any of the four questions above must provide a statement to explain such answers	Nature of Incident:	
Use this space or attach a separate sheet and return with application	Result of incident:	
SECTION 6	Check this box if the applicant is a federal, state, or local government operated hospital, if Be sure to enter the name and address of the exempt institution in Section 1.	institution or official.
CERTIFICATION OF EXEMPTION from application fee	The undersigned hereby certifies that the applicant named hereon is a federal, state or local institution or official, and is exempt from payment of the application fee.	government-operated hospital,
Provide the name and phone number of the certifying official	Signature of certifying official (other than applicant)	ate
	Print or type name and title of certifying official Te	elephone No. (required for verification)
SECTION 7 METHOD OF PAYMENT	Make check payable to: Drug Enforcement Administration See page 4 of instructions for important information.	Mail this form with payment to:
Check one form of payment only	American Express Discover Master Card Visa	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Credit Card Number Expiration Date	U.S. Department of Justice Drug Enforcement Administration P.O. Box 28083 Washington, DC 20038-8083
Sign if paying by credit card	Signature of Card Holder	FEE IS NON-REFUNDABLE
	Printed Name of Card Holder	
SECTION 8	I certify that the foregoing information furnished on this application is true and correct.	
APPLICANT'S SIGNATURE Sign in ink	Signature of applicant	Date
	Print or type name and title of applicant  WARNING: Section 643(a)(4)(A) of Title 21, United States Code states that any person who knowingly or fraudulent information in the application is subject to imprisonment for not more than four years, a time of r	Intentionally fumishes false or not more than \$30,000, or both.
In accordance with the valid OMB control nur the time for reviewing 3. The Debt Collection II This number is require 4. PRIVACY ACT INFOR	Issued unless a completed application form has been received (21 CFR 1301.13). a Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it in their for this collection of information is estimated to instructions, searching existing data sources, gathering and maintaining the data needed, and compiled to instructions, searching existing data sources, gathering and maintaining the data needed, and compiled a moreovements Act of 1996 (PL 104-134) requires that you furnish your Taxpayer Identifying Number and/or Station of the data received the search of the sear	avierage 12 minutes per response, including not reviewing the collection of information, octal Security Number on this application.
AUTHORITY PURPOSE: ROUTINE U	Section 302 and 300 of the Controlled Substances Act of 1970 (PL 91-513) and Debt Collection in texpayer identifying number and/or social security number). To obtain information required to register applicants pursuant to the Controlled Substances Act of The Controlled Substances Act Registration Records produces special reports as required for size information from this system are made to the following categories of users for the purposes states. A Other federal law enforcement and regulatory agencies for law enforcement and regulatory agencies for law enforcement and regulatory by S. State and local law enforcement and regulatory agencies for law enforcement and regulatory of C. Persons registered under the Controlled Substances Act (PL 91-513) for the purpose of verifying.	1970. Italical analytical purposes. Disclosures of di- proses. Jurposes.
EFFECT:	Failure to complete form will preclude processing of the application. NEW - Page 2	

Form-224		N FOR REGIS							
	Supplementary Instructions and Information								
ADDITIONAL INSTRUCTIONS	Fee exe street at	ANT IDENTIFICATION - Interpretation in the second of the s	he name and address of v be included. Applican	f the fee exempt institution. It must enter a valid social:	. A physical address is security number (SSN).	required; after the			
	SECTION 2. BUSINE Mid-leve	SS ACTIVITY - Indicate on I practitioners also enter or	ly one. Practitioners als ne degree from these ch	so enter one degree from ti loices: DOM, HMD, MP, N	Ns Hist: DDS, DMD, DO D, NP, OD, PA, or RPH.	, DPM, DVM, MD or PHD			
	ADS must provide current DEA registration number of parent retail pharmacy and attach a notorized affidavit (21 CFR Part 1301.17). Affidavit must include 1) Name of parent retail pharmacy and complete address 2) Name of Long-term Care (LTC) facility and complete address 3) Permit or license number(s) and date issued of State certification to operate ADS at named LTC tacility 4) Required Statement. This affidavit is submitted to obtain a DEA registration number. If any material information is false, the Administrator may commence proceedings to deep the application under section 30 of the Act (21 U.S.C. 6224(g)). Any take or fraudulant material information contained in this affidavit may subject the person signing this affidavit, and the named corporation/partnership/business to proceedure under section 403 of the Act (21 U.S.C. 624).  5) Name of corporation operating the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy) 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name and title of corporation (parting the retail pharmacy 6) Name of corpor								
	SECTION 5. DRUG S requirem to transf	CHEDULES - Applicants tents; federal registration de er schedule II controlled su te of Registration.	should check all drug so ces not overrule state n	hedules to be handled. Ho estrictions. Check the orde	owever, applicants must or form box only if you in	still comply with state			
	SECTION 4. STATE L Applicar controls "Pending	CENSE(S) - Federal regis its should contact the local id substance number, provi f'. If state licensing authori	stration by DEA is based state licensing authority de that number on this ity is not required, indica	l upon the applicant 's com prior to completing this ap application. If a state licen ste "No".	pliance with applicable oplication. If your state is se has not yet been issu	state and local laws. requires a separate ued, indicate			
	SECTION 5. LIABILIT	Y - Applicants must answe stion, provide an explanatio	r all four questions for t	he application to be accept	ed for processing. If yo	u answered "Yes" to			
	operate	CATE OF EXEMPTION - 8 d hospitals, institutions and dittle, and telephone number	officials. The applicant	's superior or agency office	r must certify exempt st				
	SECTION 7. METHO	D OF PAYMENT - Indicate rty checks or checks draw	the desired method of a	sayment. Make checks pay	vable to "Drug Enforcem	nent Administration".			
	SECTION 6. APPLICA	ANT'S SIGNATURE - Must	be the original signatur	e (in ink) of the applicant.					
CONTACT INFORMATION	ATLANTA DIVISION ( ATTN: Registration 75 Spring Street, SW, Atlanta, GA 30303		DETROIT DIVISION 0 431 Howard Street Detroit, MI 45226		PHILADELPHIA DIVI: William J. Green Fede 800 Arch Street, Roon Philadelphia, PA 1910	oral Building n 10224			
1.INTERNET	Georgia North Carolina	(000) 069-9935 (000) 219-0659	Kentucky Michigan Ohio	(500) 230-6544 (500) 230-6544 (500) 230-6544	Delaware Pennsylvania	(688) 393-8231 (688) 393-8231			
www.deadlversion.usdoj.gov 2. TELEPHONE Headquarters Call Center	Tennessee BOSTON DIVISION O	(866) 533-6953 (888) 219-7895 FFICE	EL PASO DIVISION O El Paso Federal Justio 600 South Mesa Hills El Paso, TX 79912	e Center 3010 N. 2nd Stre		at, Suite 301			
(800) 852-9539	JFK Federal Building 15 New Sudbury Stree Boston, MA 02203-01;	k, Room E400	New Mexico	(915) 532-6014	Arizona	(600) 741-0902			
5. WRITTEN INQUIRIES DEA P.O. Box 26065	Connecticut Maine	(617) 557-2200 (666) 272-5174	HOUSTON DIVISION 1433 West Loop South Houston, TX 77027-95	OFFICE	SAN DIEGO DIVISION 4580 Viewridge Avenu San Diego, CA 92123	ie .			
Washington DC 20038-8083	Massachusetts New Hampshire Rhode Island	(617) 557-2485 (666) 272-5174 (617) 557-2200	Texas (S. & Central)		California (Southern)				
4. DEA OFFICES DEA Offices are listed (890, 877, and 888	CARIBBEAN DIVISIO P.O. Box 2167		LOS ANGELES DIVIS 255 East Temple Street Los Angeles, CA 9001	at, 20th Floor	SAN FRANCISCO DR 450 Golden Gate Aver P.O. Box 36035 San Francisco, CA 94	nue, 14th Floor			
are toll-free numbers)	San Juan, PR 00922-3 Puerto Rico		California (S. Central)	(213) 621-6960	California (Northern)	(000) 304-3251			
	U.S. Virgin Islands CHICAGO DIVISION	(767) 775-1766 (767) 775-1766 DEFICE	Hawaii Nevada Trust Territory	(655) 415-9522 (655) 415-9522 (213) 594-2216	SEATTLE DIVISION ( 400 Second Avenue, V Seattle, WA 98119				
	Kluczynski Federal Bu 230 S. Dearborn Stree Chicago, IL 60604	ilding	MIAMI DIVISION OFF 6400 N.W. 53rd Street Miami, FL 33166		Alaska Idaho	(600) 219-4261 (600) 219-4261			
	Illinois Indiana Minnesota	(312) 353-1234 (312) 353-1238 (312) 353-1238	Florida NEWARK DIVISION O	(305) 590-4880 DESIGN	Oregon Washington ST. LOUIS DIVISION	(688) 219-4261 (688) 219-1416			
	North Dakota Wisconsin	(312) 353-9166 (312) 353-9166 (312) 353-1236	80 Mulberry Street, 2n Newark, NJ 07102		317 South 16th Street St. Louis, MO 63103				
	DALLAS DIVISION O 10160 Technology Blv Dallas, TX 75220 Oklahoma	lowa Kansas Missouri Nebraska South Dakota	(600) 803-1179 (600) 803-1179 (600) 803-1179 (600) 803-1179 (600) 803-1179						
	Oktahoma         (888) 338-4704         Lakeway III, Sulla 1800         South Daketa         (886) 308-4704           Taxas (Northern)         (888) 338-4704         Metahik, LA 70002         WASHINGTON, D.C. DIVISION OF DEVISION								
	Colorado Montana Utah Wyoming	(800) 328-6900 (800) 328-6900 (800) 328-6900 (800) 328-6900	Mississippi NEW YORK DIVISION 99 Tenth Avenue New York, NY 10011	(655) 514-7302	District of Columbia Maryland Virginia West Virginia	(677) 801-7974 (677) 330-6670 (677) 801-7974 (677) 330-6670			
NEW INST - Page 3	<u>-</u>	-	New York	(877) 883-8789 (212) 337-1893 (212) 337-1894	-				

DRUG					
SCHEDULE   SCHEDULE   SCHEDULE     SCHEDULE	DRUG	Listed below are examples of the schedules with assis	ned drug code nu	mbers. If you are in need of additional information, see 21 C	FR 1306
MARCOTTC & INCA-MARCOTTC   MARCOTTC BASIC CLASSES   CODE	SCHEDULES	or contact the DEA office serving your area.			
BASIC CLASSES   COCE	l .	SCHEDULE I		SCHEDULE III	
Acatophible	l .		0006	NARCOTIC BASIC CLASSES	CODE
Acayimishadol Aligheode March 19801 Ethybeocoblashus 15 06 might size the ingradients of the properties of the propertie		BASIC CLASSES	OOGE	Buprenorphine	9064
Allystrodine Allystrodine Allystrodine Allystrodine Allystrodine up to 15 mg/but plus other ingreduents Allystrodine up to 15 mg/but plus other ingreduents Occording to 15 mg/but plus other ingreduents Occo				Codelne up to 90 mg/du plus other ingredients	
Ajrincockynemics				Dinydrocode neup to so mg/du plus other ingredients	
Bufchanke   7433		Ainhacolulmothadol (ovcont I A AM)			
Deutemoremis    Deutemoremoremis    Deutemor		Burotenine		Morphine up to 50 mg/100ml or am plus other ingred.	
2,5 - briefstreysening (MMA)		Dextromoramide		Oplum up to 500 mg/100m, plus other active ingred.	9009
Directifystripstarinal (DMT)		Diethyltryptamine (DET)			
Biorphine   accept hydrochroids salk		2,5 - Dimetroxyampnetamine (DMA) Dimetrostamine (DMT)		NON-MARCOTIC BASIC CLASSES	CODE
Barrena I		Etorphine (except hydrochloride salt)		Anabolic Signoids	4000
Ibogatina   7260		gamma-Hydroxybutyric acid (except drug product)	2010	Berzphetamine	1220
National Content					
Lysergic acid dishrylamida (LSD)					
Markushan   7560   Mathyryton   2277   Mascaline   2277   Mathematical puls noncortrolled active ingredients   2277   2278   2278   2279   2					
Mescalina   7311		Marhuana			
3.4 Metrylysenodioxyambamphatemina (MDA)   7400   Penendmistratina   1615   3.4 Metrylysenodioxyambamphatemina (MDA)   7400   Penendmistratina   1615   3.216		Mescaline	7351	Periobarbital plus noncontrolled active ingredients	2271
3.4.		Methaguaione		Peniobarbital suppository	
Description   Property   Proper					
Payolic   Titlopenist   2200					
Pallogiph					2329
Palodyin				Vinbarbital	2335
Tairaniyinocannaholic (THC)					
1-[1-[2-Thienylcyclohexyl-piperidine 7470 NARCOTIC BASIC CLASSES CODE  SCHEDULE II Dectropropoxyphane du 0276 01670 NARCOTIC BASIC CLASSES CODE  Alphaprodine 9010 Apricolam 2002 Apricolam 2002 Apricolam 2002 Apricolam 2002 Apricolam 2003 Aprico				SCHEDULE IV	
SCHEDULE	l .				CODE
NARCOTIC BASIC CLASSES	l .				
Alphaprodine	l .				
Anisordine	l .			NON-NARCOTIC BASIC CLASSES	CODE
Cocaline				Alorzolam	2002
Codeline				Barbital	
Diphenoxylate		Codelne	9050		
Disranciphina (M50-50)   0056		Dextropropoxyphene (bulk)			
Brymorphine   1900		Diphenoxylate Disconnection (MSO 50)			
Brophine Hydrochloride (M-99)   9059   Ferrituramhe   1670		Ethylmorphine			
Hydrocodone		Etorphine Hydrochloride (M-99)	9059		
Hightomorphone					
Lavo alphacetylmethadol (LAAM)		Hydrocodone		Lorazepam	
Levorphanol 9220 Meoutamise 2200 Meprotarbial (Methylphenobarbital) 2250 Meprobarbial (Methylphenobarbital) 2250 Methodore 9250 Meprobarbial (Methylphenobarbital) 2250 Methodore 9250 Methodorial 2264 Optim, powdered 9830 Midacolam 2264 Optim, raw 9800 Oxazepam 2265 Oxyodoren 9143 Paraldehyde 2265 Oxyodoren 9143 Pernoline 9852 Oxyodoren 9871 Penalzodine 9709 Poppy Straw 9870 Phenobarbital 2265 Thebaine 9333 Pheniarmine 1640 Pracepam 2764 NON-NARCOTIC BASIC CLASSES OCCE Quazepam 2261 Amobarbital 2125 Trazolam 2261 Amobarbital 2125 Trazolam 2261 Amobarbital 1100 Zolpidem 2763 Methylphenidate 1105 Methylphenidate 1724 Peniobarbital 2270 SCHEDULE V Phenoydidine (PCP) 7471 Phenomitizatine 6311		Levo-alphacetylmethadol (LAAM)		Mazindol	1605
Mepridicine   9230   Mepriobarbital (Methylphenicoarbital)   2250		Leverphanol	9220		
Merphine		Meperidine			
Michael					
Oplum, raw         9800         Oxazapam         2835           Oxyoodone         9143         Paraldshyds         2806           Oxyoodone         9852         Pemoline         1530           Poppy Straw         9871         Peniszcolne         9700           Poppy Straw Concentrate         9870         Phonobarbital         2205           Thebalne         9333         Phonisrmhe         1640           Pracepam         2764         2764           NON-NAROOTIC BASIC CLASSES         CODE         Quazepam         2801           Amobarbital         2125         Thazolam         2057           Amobarbital         1100         Zolpidem         2763           Methyphonidate         1105         Methyphonidate         1724           Pentobarbital         2270         SCHEDULE V           Phonographic         6831         CODE           Phonographic         6831         CODE					
Okycodone         0143         Parallehylde         2505           Oxymorphone         0852         Pemoline         1530           Poppy Straw         0870         Phenobarbital         2205           Poppy Straw Concentrate         0870         Phenobarbital         2205           Thebaine         9333         Phenoterbital         1840           NON-NARCOTIC BASIC CLASSES         OODE         Quazepam         2061           Amobarbital         2125         Thazolam         2067           Amphetamine         1100         Zolpidem         2763           Methylphenidate         1105         Verencountial         2270           Methylphenidate         1224         SCHEDULE V           Phenoydidine (PCP)         7471         Phenoydidine (PCP)           Phenoydidine (PCP)         631         CODE		Oplum, raw	9800	Oxazepam	
Peristrodine		Okycodone			
Poppy Straw Concentrate					
Thebaine		Poppy Straw Concentrate		Phenobarbital	2285
NON-NARCOTIC BASIC CLASSES		Thebaine			
Temszlopam   2025   Temszlopam   2025   Temszlopam   2026   Temszlopam   2026   Temszlopam   2027   Tems		NON NARCOTIC BASIC CLASSES	0006		
Amobarbital 2125 Triszotaim 2807 Amphatamine 1100 Zolpidem 2763  Merhamphatamine 1105 Methylphenidate 1724 Pentobarbital 2270 SCHEDULE V Phencydidine (PCP) 7471 Phanmalrazine 1631 CODE Phonylazatone 5501		NUM-RAPVOUTIC BASIC CLASSES	3306	Temazepam	2925
Methamphatamine		Amobarbital	2125	Triazolam	
Methylphonidate   1724				Zolpidem	2763
Penticibarbital   2270   SCHEDULE V					
Phenoyolidine (PCP)         7471         SNESSEE           Phenometratine         1631         CODE           Phenylacatione         5901         CODE				SCHEDINEV	
Phenmetrazine 1631 CODE Phenylacetone 5501		Phencyclidine (PCP)	7471	SUMEDULE V	
		Phenmetrazine			CODE
Codeline Cough Preparation (200mg/100ml or 100g) 9100		Prienylacetone Secobarbital		Codeles Court Describes (200-sald05-1	2400
		written and a sail	2010	Coderne Cough Preparation (200mg/100m) or 100g)	9100

Notice to Registrants Making Payment by Check

Authorization to Convert Your Check: If you send us a check to make your payment, your check will be converted into an electronic fund transfer. "Electronic fund transfer" is
the term used to refer to the process in which we electronically instruct your financial studies to the start used to refer to the processing your
check. By sending your completed, signed check to us, you authorize us to copy your check and to use the account information from your check to make an electronic fund
transfer from your account for the same amount as the check. If the electronic fund transfer cannot be processed for lectnical reasons, you authorize us to process the copy of your check: insufficient Funds: The electronic funds transfer from your account will usually occur with 24 hours, which is faster than a check is normally processed. Therefore, make sure

there are sufficient funds available in your checking account when you send us your check. If the electronic funds transfer cannot be completed because of insufficient funds, we may try to make the transfer up to two times.

Transaction information: The electronic fund transfer from your account will be on the account statement you receive from your financial institution. However, the transfer may be in a different place on your statement than the place where your checks normally appear. For example, it may appear under "other withdrawals" or "other transactions." You will not neceive your original check back from your financial institution. For security reasons, we will destroy your original check, but we will keep a copy of the check for record-keeping purposes.

Your Plights: You should contact your financial institution immediately if you believe that the electronic fund transfer reported on your account statement was not properly authorized or is otherwise incorrect. Consumers have protections under Federal law called the Electronic Fund Transfer Act for an unauthorized or incorrect electronic fund

NEW INST - Page 4

RENEWAL APPLICATION FOR REGISTRATION Form-224a APPROVED OMB NO 1117-0014 FORM DEA-224a (1-05) Under the Controlled Substances Act To renew by mail complete this application. Keep a copy for your records.
 Print clearly, using black or blue ink, or use a typewriter.
 Section 5 should be completed only if your information has changed.
 Mail this form to the address provided in Section 6 or use enclosed envelope.
 Include the correct payment amount. FEE IS NON-REFUNDABLE.
 If you have any questions call 800-882-9539 prior to submitting your application.
 Save time - renew online at www.deadiversion.usdoj.gov. INSTRUCTIONS REGISTRATION INFORMATION: DFA# REGISTRATION EXPIRES IMPORTANT: DO NOT SEND THIS APPLICATION AND RENEW ONLINE FEE IS NON-REFUNDABLE SECTION 1 Schedule IV Schedule II Narcotic Schedule III Narcotic DRUG SCHEDULES Schedule II Non-Narcotic Schedule III Non-Narcotic Schedule V Check all that apply SECTION 2 Check this box if you need official order forms - for the purchase of schedule II narcotic/schedule II non-narcotic controlled substances SECTION 3 A. Are you currently authorized to prescribe, distribute, dispense, conduct research, or otherwise handle the controlled substances in the schedules for which you are applying under the laws of the state or jurisdiction in which you are operating or propose to operate? STATE LICENSE(S) YES NO State License Number Be sure to include both state license numbers if applicable State Controlled Substance License Number (if required) IMPORIANT:
If you answered yes to these question(s) on previous application, you must continue to answer yes and provide a statement of explanation.

To nederal law?

To nederal law?

On nederal law?

C. Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted, or denied?

D. Has the applicant ever surrendered (for cause) or had a state professional license or the registration revoked, suspended, denied. restricted YES NO D. Has the applicant ever surrendered (for cause) or had a state professional license or controlled substance registration revoked, suspended, denied, restricted, or placed on probation? Is any such action pending? E. If the applicant is a corporation (other than a corporation whose stock is owned and traded by the public), association, partnership, or pharmacy, has any officer, partner, stockholder, or proprietor been convicted of a crime in connection with controlled substances under state or federal law, or ever surrendered, for cause, or had a federal controlled substance registration revoked, suspended, restricted, denied, or ever had a state professional license or controlled substance registration revoked, suspended, denied, restricted or placed on probation? All questions in this section must be answered. SECTION 4 EXPLANATION OF "YES" ANSWERS Date(s) of incident: \_\_\_\_ Location(s) of incident: \_ Nature of incident: Applicants who have answered "YES" to questions B, C, D, or E above must provide a statement to explain such answers Use this space or attach a separate sheet and return with application Result of incident:

RENEWAL - Page 1

SECTION 5	Last Name (if registration is for individual) -OR- Business Name (if registration is for business)	
CHANGES TO	Control (in registration is to manually of Control (in registration in the district)	<del></del>
APPLICANT IDENTIFICATION		
IDENTIFICATION	First Name and Middle Initial	- N N
DEDT COLLECTION		TYYNULL.
DEBT COLLECTION INFORMATION	Tax Identification Number (if registration is for business) Social Security Number (if registration is for	individual)
Mandatory pursuant		Provide SSN or TIN.
to Debt Collection Improvements Act		See note #3 on bottom of page 2
	Address Line 1 (street address)	
IMPORTANT	Address Line 2	
Leave this section		
blank unless the registration		
information on front page	City	e Zip Code
is incorrect.		11111181111
	B Isiness Phone Number Business Fax Number	
SECTION 6	Make check payable to: Drug Enforcement Administration	
METHOD OF	Check See page 4 of instructions for important information.	
PAYMENT		Mail this form with payment to:
Check one form of payment only	American Express Discover Master Card Visa	U.S. December of the Fee
payment only	Credit Card Number Expiration Date	U.S. Department of Justice  Drug Enforcement Administration
		P.O. Box 105616
		Atlanta, GA 30348-5616
Sign if paying by		
credit card	Signature of Card Holder	FEE IS NON-REFUNDABLE
	Pid-Allers (O-Allelle	
	Printed Name of Card Holder	
SECTION 7	Check this box if the applicant is a federal, state, or local government operated hospital, in:	stitution or official.
CERTIFICATION	Be sure to enter the name and address of the exempt institution on address lines 1 and 2 in Sec current registration certificate.	tion 5, if it is not already on your
OF EXEMPTION from application fee	The undersigned hereby certifies that the applicant named hereon is a federal, state or local government op	erated hospital, institution or official,
	and is exempt from payment of the application fee.	
Provide the name and		
phone number of the certifying official	Signature of certifying official (other than applicant)	te
	Print or type name and title of certifying official Tele	ephone No. (required for verification)
SECTION 8	I certify that the foregoing information furnished on this application is true and correct.	
APPLICANT'S		
SIGNATURE	Signature of applicant	Date
Sign in ink		
	Print or type name and title of applicant	
	WARNING: Section 843(a)(4)(A) of Title 21, United States Code states that any person who knowingly or in	
	fraudulent information in the application is subject to imprisonment for not more than four years, a fine of no	ot more than \$30,000, or both.
	issued unless a completed application form has been received (21 CFR 1301.13).	
valid OMB control nu	e Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displ mber for this collection is 1117-0014. Public reporting burden for this collection of information is estimated to ave	rage 12 minutes per response, including
the time for reviewing 3. The Debt Collection I	instructions, searching existing data sources, gathering and maintaining the data needed, and completing and re mprovements Act of 1996 (PL 104-134) requires that you furnish your Taxpayer Identifying Number and/or Social	eviewing the collection of information.
This number is requir 4. PRIVACY ACT INFO	ed for debt collection procedures should your fee become uncollectable. RMATION	
AUTHORIT	Y: Section 302 and 303 of the Controlled Substances Act of 1970 (PL 91-513) and Debt Collection Improtaxpayer identifying number and/or social security number).	vements Act of 1996 (PL 104-134) (for
PURPOSE: ROUTINE L	To obtain information required to register applicants pursuant to the Controlled Substances Act of 197	0. al analytical purposes. Disclosures of
ROUTINE	information from this system are made to the following categories of users for the purposes stated:	
	A. Other federal law enforcement and regulatory agencies for law enforcement and regulatory purpos     B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purpos	ses.
EFFECT:	C. Persons registered under the Controlled Substances Act (PL 91-513) for the purpose of verifying th Failure to complete form will preclude processing of the application.	e registration of customers.
	RENEWAL - Page 2	

\_\_\_\_\_\_

	—	ON FOR RENEV	VAL						
	Supplementary	Instructions and Ir	formation						
ADDITIONAL INSTRUCTIONS	requirer	SCHEDULES - Applicants nents; federal registration of fer schedule II controlled su	loes not overrule state re						
	SECTION 2. ORDER FORMS - Order forms will be mailed to the registered address following issuance of a Certificate of Registration.								
,	SECTION 3. STATE LICENSE(S) - Federal registration by DEA is based upon the applicant 's compliance with applicable state and local laws. Applicants should contact the local state licensing authority prior to completing this application. If your state requires a separate controlled substance number, provide that number on this application. If a state license has not yet been issued, indicate "Pending". If state licensing authority is not required, indicate "No".								
		TY - Applicants must answestion, provide an explanati							
:	reduce or new p is requir number	ANT IDENTIFICATION - E data entry errors. Enter ch phone numbers. Fee exer ed; after the street addres (SSN) on record is correct dilection information is m	anges in previously prov npt individuals should lis s a post office box may l . If renewing a business	rided registration informati it the name and address o be included. Individuals re s entity, a valid tax identific	on, such as name chang of the fee exempt institute enewing should ensure t ation number (TIN) mus	ge, address correction, ion. A physical address that the social security			
:	SECTION 6. METHO Third-pa	D OF PAYMENT - Indicate arty checks or checks draw	the desired method of p n on foreign banks will r	payment. Make checks pa not be accepted. FEES AF	ayable to "Drug Enforcer RE NON-REFUNDABLE	ment Administration".			
:	operate	ICATE OF EXEMPTION - I d hospitals, institutions and y title, and telephone numb	l officials. The applicant	's superior or agency offic	er must certify exempt s	cal government status. The signature,			
:	SECTION 8. APPLIC	ANT'S SIGNATURE - Musi	be the original signatur	e (in ink) of the applicant.					
CONTACT	1. INTERNET: 2. TELEPHONE: 3. WRITTEN INQUIR	Headquarters Cal	Center: (800) 882-9539 t Administration	at www.deadiversion.usdo	oj.gov				
•	4. DEA OFFICES: DE	A Offices are listed below (	800, 877, and 888 are to	oll-free numbers).					
	ATLANTA DIVISION ATTN: Registration 75 Spring Street, SW, Atlanta, GA 30303		DETROIT DIVISION O 431 Howard Street Detroit, MI 48226		PHILADELPHIA DIVI William J. Green Fed 600 Arch Street, Rooi Philadelphia, PA 1910	eral Building m 10224			
	Georgia North Carolina South Carolina	(888) 869-9935 (888) 219-8689 (866) 533-6983	Kentucky Michigan Ohio	(800) 230-6844 (800) 230-6844 (800) 230-6844	Delaware Pennsylvania	(888) 393-8231 (888) 393-8231			
	Tennessee BOSTON DIVISION O JFK Federal Building	(888) 219-7898 DFFICE	EL PASO DIVISION O El Paso Federal Justio 600 South Mesa Hills El Paso, TX 79912	e Center	PHOENIX DIVISION 3010 N. 2nd Street, S Phoenix, AZ 85012				
	15 New Sudbury Stre Boston, MA 02203-01		New Mexico	(915) 832-6014	Arizona (800) 741-0902				
	Connecticut Maine Massachusetts	(617) 557-2200 (888) 272-5174 (617) 557-2468	HOUSTON DIVISION OFFICE 1433 West Loop South, Suite 800 Houston, TX 77027-9508		SAN DIEGO DIVISION OFFICE 4580 Viewridge Avenue San Diego, CA 92123-1637				
	New Hampshire Rhode Island	(888) 272-5174 (817) 557-2200	Texas (S. & Central)		California (Southern)	(800) 284-1152			
	Vermont CARIBBEAN DIVISIO P.O. Box 2167	(888) 272-5174 ON OFFICE	LOS ANGELES DIVIS 255 East Temple Street Los Angeles, CA 9001	SION OFFICE et, 20th Floor	SAN FRANCISCO DI 450 Golden Gate Ave P.O. Box 36035 San Francisco, CA 94	nue, 14th Floor			
	San Juan, PR 00922-		California (S. Central)	(213) 621-6960	California (Northern)	(888) 304-3251			
1	Puerto Rico U.S. Virgin Islands CHICAGO DIVISION	(787) 775-1766 (787) 775-1766 OFFICE	Hawaii Nevada Trust Territory	(888) 415-9822 (888) 415-9822 (213) 894-2216	SEATTLE DIVISION 400 Second Avenue, Seattle, WA 98119				
	Kluczynski Federal Bu 230 S. Dearborn Stre Chicago, IL 60804	uilding	MIAMI DIVISION OFF 8400 N.W. 53rd Street Miami, FL 33166	ICE t	Alaska Idaho Oregon	(888) 219-4261 (888) 219-4261 (888) 219-4261			
	Illinois Indiana	(312) 353-1234 (312) 353-1236	Florida	(305) 590-4880	Washington	(888) 219-1418			
	Minnesota North Dakota Wisconsin	(312) 353-9166 (312) 353-9166 (312) 353-1236	NEWARK DIVISION 0 80 Mulberry Street, 2n Newark, NJ 07102		ST. LOUIS DIVISION 317 South 18th Stree St. Louis, MO 63103	OFFICE t			
	DALLAS DIVISION O 10160 Technology Blv Dallas, TX 75220	d., East	New Jersey  NEW ORLEANS DIVI 3838 N. Causeway Bh	vd	lowa (888) 803-1179 Kansas (888) 803-1179 Missouri (888) 803-1179 Nebraska (888) 803-1179				
	Oklahoma (888) 336-4704 Lakeway III, Suite 1800 South Dakota (888) 803-1179 Texas (Northern) (888) 336-4704 Metainie, LA 70002								
	DENVER DIVISION OFFICE Alabama (888) 514-8051 Techworld Plaza 115 Inverness Drive, East Arkansas (888) 514-7302 800 K Street, N.W., Suite 500 Englewood, CO 80112 Louisiana (888) 514-7302 Washington, D.C. 20001 Mississippi (888) 514-7302					uite 500			
	Colorado Montana Utah Wyoming	(800) 326-6900 (800) 326-6900 (800) 326-6900 (800) 326-6900	NEW YORK DIVISION 99 Tenth Avenue New York, NY 10011	. ,	District of Columbia Maryland Virginia West Virginia	(877) 801-7974 (877) 330-8670 (877) 801-7974 (877) 330-8670			
RENEWAL INST - Page 3			New York	(877) 883-5789 (212) 337-1593 (212) 337-1594					

DRUG SCHEDULES	Listed below are examples of the schedules with assig or contact the DEA office serving your area.	jned drug code r	numbers. If you are in need of additional information, see 21 C	FR 1308
	SCHEDULE I		SCHEDULE III	
	NARCOTIC & NON-NARCOTIC BASIC CLASSES	CODE	NARCOTIC BASIC CLASSES	CODE
	Acetorphine	9319	Buprenorphine Codeine up to 90 mg/du plus other ingredients	9064 9319
	Acetylmethadol	9601	Dihydrocodeineup to 90 mg/du plus other ingredients	9807
	Allylprodine Alphacetylmethadol (except LAAM)	9602 9603	Ethylmorphine up to 15 mg/du plus other ingredients Hydrocodone up to 15 mg/du plus other ingredients	9808 9806
	Bufotenine (except LAAM)	7433	Morphine up to 50 mg/100ml or gm plus other ingredients	9810
	Dextromoramide	9813	Opium up to 500 mg/100m. plus other active ingred.	9809
	Diethyltryptamine (DET)	7434		
	2,5 - Dimethoxyamphetamine (DMA) Dimethyltryptamine (DMT)	7396 7435	NON-NARCOTIC BASIC CLASSES	CODE
	Dimethyltryptamine (DMT) Etorphine (except hydrochloride salt)	7435 9056	Anabolic Steroids	4000
	gamma-Hydroxybutyric acid (except drug product)	2010	Benzphetamine	1228
	Heroin	9200	Butalbital	2100
	Ibogaine	7260	Dronabinol Pharmaceutical Product	7389
	Ketobemidone	9628 7215	GHB Drug Product (gamma-Hydroxybutyric acid)	2010
	Lysergic acid diethylamide (LSD) Marihuana	7315 7360	Ketamine Methyprylon	7285 2575
	Mannuana Mescaline	7381	Metnyprylon Pentobarbital plus noncontrolled active ingredients	2271
	Methaqualone	2565	Pentobarbital suppository	2271
	3,4 - Methylenedioxyamphetamine (MDA)	7400	Phendimetrazine	1615
	3,4 - Methylenedioxymethamphetamine (MDMA)	7405	Secobarbital plus noncontrolled active ingredients	2316
	n- Ethyl - 1 - Phenylcyclohexylamine (PCE) Peyote	7455 7415	Secobarbital suppository Thiopental	2316 2329
	1 - (1-Phenylcyclohexyl)pyrrolidine (PCP)	7415 7458	Vinbarbital	2329
	Psilocybin	7437	VIIIDAIDIIAI	2000
	Psilocyn	7438		
	Tetrahydrocannabinols (THC)	7370	SCHEDULE IV	
	1-[1-(2-Thienyl)-cyclohexyl]-piperidine	7470	NARCOTIC BASIC CLASSES	CODE
	SCHEDULE II		Dextropropoxyphene du Difenoxin 1mg/25ug atropine SO4/du	9278 9167
	NARCOTIC BASIC CLASSES	CODE	NON-NARCOTIC BASIC CLASSES	CODE
	Alphaprodine	9010		
	Anileridine	9020	Alprzolam Barbital	2882 2145
	Cocaine Codeine	9041 9050	Chloral Hydrate	2145
	Dextropropoxyphene (bulk)	9050 9273	Chlordiazepoxide	2744
	Diphenoxylate	9170	Clorazepate	2768
	Diprenorphine (M50-50)	9058	Diazepam	2765
	Ethylmorphine `	9190	Diethylpropion Fenfluramine	1610 1670
	Etorphine Hydrochloride (M-99)	9059 2550	Fentiuramine Flurazepam	2767
	Glutethimide Hydrocodone	2550 9193	Halazepam	2762
	Hydromorphone	9193 9150	Lorazepam	2885
	Levo-alphacetylmethadol (LAAM)	9648	Mazindol	1605
	Levorphanol	9220	Mebutamate Mephobarkital (Methylobenebarkital)	2800
	Meperidine	9230	Mephobarbital (Methylphenobarbital) Meprobamate	2250 2820
	Methadone Morphine	9250 9300	Methohexital	2264
	Morphine Opium, powdered	9300 9639	Midazolam	2884
	Opium, powdered Opium, raw	9600	Oxazepam	2835
	Oxycodone	9143	Paraldehyde	2585
	Oxymorphone	9852	Pemoline Pentazocine	1530 9709
	Poppy Straw Concentrate	9871	Pentazodne Phenobarbital	2285
	Poppy Straw Concentrate Thebaine	9870 9333	Phentermine	1640
	Thebaine	8000	Prazepam	2764
	NON-NARCOTIC BASIC CLASSES	CODE	Quazepam	2881
			Temazepam Triazolam	2925
	Amobarbital	2125	Triazolam Zolpidem	2887 2783
	Amphetamine Methamphetamine	1100 1105	Zoipidem	2100
	Methamphetamine Methylphenidate	1105 1724		
	Pentobarbital	2270	SCHEDULE V	
	Phencyclidine (PCP)	7471	SCHEDULE V	
	Phenmetrazine	1631		CODE
	Phenylacetone Secobarbital	8501 2315		
		2216	Codeine Cough Preparation (200mg/100ml or 100g)	9100

Notice to Registrants Making Payment by Check

Authorization to Convert Your Check: If you send us a check to make your payment, your check will be converted into an electronic fund transfer. "Electronic fund transfer" is the term used to refer to the process in which we electronically instruct your financial institution to transfer funds from your account to our account, rather than processing your check. By sending your completed, signed check to us, you authorize us to copy your check and to use the account information from your check to make an electronic fund transfer from your account for the same amount as the check. If the electronic fund transfer cannot be processed for technical reasons, you authorize us to process the copy of your check.

Insufficient Funds: The electronic funds transfer from your account will usually occur with 24 hours, which is faster than a check is normally processed. Therefore, make sure there are sufficient funds available in your checking account when you send us your check. If the electronic funds transfer cannot be completed because of insufficient funds, we may try to make the transfer up to two times.

Transaction Information: The electronic fund transfer from your account will be on the account statement you receive from your financial institution. However, the transfer may

be in a different place on your statement than the place where your checks normally appear. For example, it may appear under "other withdrawals" or "other transactions." You will not receive your original check back from your financial institution. For security reasons, we will destroy your original check, but we will keep a copy of the check for recordkeeping purposes

Your Rights: You should contact your financial institution immediately if you believe that the electronic fund transfer reported on your account statement was not properly authorized or is otherwise incorrect. Consumers have protections under Federal law called the Electronic Fund Transfer Act for an unauthorized or incorrect electronic fund transfer.

RENEW AL INST - Page 4

Form-363	APPLICATION FOR REGISTRATION	APPROVED OMB NO 1117-0015 FORM DEA-363 (11-05)	
	Under the Narcotic Addict Treatment Act of 1974	Previous editions are obsolete	
INSTRUCTIONS	To apply by mail complete this application. Keep a copy for your records.     Print clearly using black or blue ink, or use a typewriter.	REGISTRATION INFORMATION:	
l	Print clearly using black or blue ink, or use a typewriter.     Section 1 Should be completed only 17 your information has changed.     Mail this form to the address provided in Section 8 or use enclosed envelope.		
l	<ol> <li>Include the correct payment amount. FEE IS NON-REFUNDABLE.</li> <li>If you have any questions contact 800-882-9939 prior to submitting your application.</li> <li>Save time - apply online at wave-deadlyersion.uedoj.gov.</li> </ol>		
l	IMPORTANT: DO NOT SEND THIS APPLICATION AND APPLY ONLINE.		
l			
l			
l			
l		Fee for 1 year is \$130	
		FEE IS NON-REFUNDABLE	
SECTION 1 APPLI	ICANT TIFICATION		
Business or Facility	Name (If registration is for business entity or is fee exempt)		
5			
Business or Facility	Name 2 ("doing business as", continuation of business name, or name of fee e	xempt institution)	
Address Line 1 (stre	et address)		
Address Line 2			
City		State Zip Code	
Business Phone Nu	mber Business Fax Number		
DEBT COLLECTION			
INFORMATION	Tax Identification Number		
Mendatory pursuant to Debt Collection Improvements Act	See note #3 on bottom of page 2.		
SECTION 2	□ NTP - Maintenance □ NTP - Co	mpounder / Maintenance	
BUSINESS ACTIVITY	□ NTP - Detoxification □ NTP - Co	mpounder / Detoxification	
Check one box only	□ NTP - Maintenance and Detoxification □ NTP - Co	mpounder / Maintenance and Detoxification	
SECTION 3	Schedule II Schedul	e III	
DRUG SCHEDULES			
Check all that apply	Check this box if you require official order forms - for purchase or transfer of	schedule II controlled substances.	
SECTION 4 A	re you currently authorized by the Food and Drug Administration for the busines	ss activity described in this application?	
	YES PENDING NO		
Mandatory for approval		FDA Number	
SECTION 5 Are the s	you currently authorized to prescribe, distribute, dispense, conduct research, or chedules for which you are applying under the laws of the state or jurisdiction i	otherwise handle the controlled substances in n which you are operating or propose to operate?	
STATE LICENSE(S)	YES, I have a license	State License Number	
ı	NOT REQUIRED by this state		
	NEW - Page 1		

SECTION 6	Has the applicant ever been convicted of a crime in connection with controlled substance.	es under state or federal law?	
LIABILITY	. Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted, or denied?		
IMPORTANT: All questions in this section must	<ol><li>Has the applicant ever surrendered (for cause) or had a state professional license or cont revoked, suspended, denied, restricted, or placed on probation? Is any such action per</li></ol>	rolled substance registration   □ □	
be answered.	If the applicant is a comporation (other than a corporation whose stock is owned and traded by the public), association, partnership, or pharmacy, has any officer, partner, stockholder, or proprietor been convicted of a crime in connection with controlled substances under state or federal allaw, or ever surrendered, for cause, or had a federal controlled substance registration revoked, suspended, restricted, denied, or ever had a state professional license or controlled substance registration revoked, suspended, denied, restricted or placed on probation?		
EXPLANATION OF "YES" ANSWERS	Date(s) of incident: Location(s) of incident:		
Applicants who have answered "YES" to any of the four question above must provide a statement to explain such answers	Nature of incident:		
Use this space or affact a separate sheet and return with application	h Result of incident:		
SECTION 7	Check this box if the applicant is a federal, state, or local government-operated narcoti Be sure to enter name and address of the exempt institution in Section 1.		
OF EXEMPTION from application fee	The undersigned hereby certifies that the applicant named hereon is a federal, state or loo treatment program, and is exempt from payment of the application fee.	al government-operated narcotic	
Provide the name and phone number of the certifying official	Signature of certifying official (other than applicant)	Date	
'	Print or type name and title of certifying official	Telephone No. (required for verification)	
SECTION 8 METHOD OF PAYMENT	Check Make check payable to: Drug Enforcement Administration See page 3 of instructions for important information.	Mall this form with payment to:	
Check one form of payment only	American Express Discover Master Card Visa  Credit Card Number Expiration Date	U.S. Department of Justice	
		Drug Enforcement Administration P.O. Box 28083 Washington DC 20038-8083	
Sign if paying by credit card	Signature of Card Holder	FEE IS NON-REFUNDABLE	
	Printed Name of Card Holder		
SECTION 9	I certify that the foregoing information furnished on this application is true and correct.		
APPLICANT'S SIGNATURE Sign in ink	Signature of applicant Date		
ı	Print or type name and title of applicant		
	WARNING: Section 643(a)(4)(A) of Title 21, United States Code states that any person who knowingly fraudulent information in the application is subject to imprisonment for not more than four years, a fine	or intentionally furnishes false or of not more than \$30,000, or both.	
1. No registration will be issued unless a completed application form has been received (21 CFR 1301.13). 2. In accordance with the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid CMB control number. The valid CMB control number for this collection is 1117-0015. Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. 3. The Debt Collection improvements Act of 1906 (Pt. 104-134) requires that you trunkly your Taxpayer Identifying Number and/or Social Security Number on this application. This number is required for debt collection procedures should your fee become uncollectable. 4. PRIVACY ACT INFORMATION.			
PURPOSE:	AUTHORITY: Section 302 and 303 of the Controlled Substances Act of 1970 (PL 91-513) and Debt Collection improvements Act of 1998 (PL 104-134) (for texpayer identifying number analysis security number).  PURPOSE: To obtain information required to register applicants pursuant to the Controlled Substances Act of 1970.  The Controlled Substances Act Registration Records produces special reports as required for statistical analytical purposes. Disclosures of information from this system are made to the following calegories of users for the purposes stated:  A Other laderal taw enforcement and regulatory agancies for law enforcement and regulatory purposes.		
State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes.     C. Persons registered under the Controlled Substances Act (PL 91-513) for the purpose of verifying the registration of customers.     Failure to complete form will preclude processing of the application.     NEW - Page 2			

.....

Form-363	PPLICATION FOR REGISTRATION	
1 01111-000	upplementary Instructions and Information	
ADDITIONAL INSTRUCTIONS	ECTION 1. APPLICANT IDENTIFICATION - Information must be typed or printed in the blocks preduce data entry errors.	rovided to help
	Fee exempt applicant should list the name and address of the fee exempt institution A physical address is required; a post office box may be included after the street ad-	dress.
	Applicant must enter a valid tax identification number (TIN).  Debt collection information is mandatory pursuant to the Debt Collection Improvement Act of 1996.	
	ECTION 2. BUSINESS ACTIVITY. Indicate only one.	
	ECTION 3. DRUG SCHEDULES - Applicant should check all drug schedules to be handled. However, applicant must still comply with state requirements; federal registration does not overrule state restrictions.	
	Check the order form box only if you intend to purchase or to transfer schedule II co substances. Order forms will be mailed to the registered address following issuance Certificate of Registration.	ntrolled ofa
	ECTION 4. FDA PERMIT - Authorization by the Food 8 Drug Administration is mandatory for DE approval. Enter the status of your FDA authorization and the FDA number.	A Registration
	ECTION 5. STATE LICENSE(S) - Federal registration by DEA is based upon the applicant 's cor applicable state and local laws.	mpliance with
	Applicant should contact the local state licensing authority prior to completing this ap Check that you are currently authorized by the state and provide your state license r If state licensing is not required, indicate "Not required by this state".	plication. number.
	ECTION 6. LIABILITY - Applicant must answer all four questions for the application to be accept	ed for processing.
	If you answered "Yes" to any question, provide an explanation in the space provided If additional space is required, you may attach a separate sheet of paper.	
	ECTION 7. CERTIFICATE OF EXEMPTION - Exemption from payment of application fee is limit state or local government-operated narcotic treatment program.	ted to federal,
	The applicant's superior or agency officer must certify exempt status. The signature and telephone number of the certifying official (other than the applicant) must be pro	, authority title, vided.
	ECTION 8. METHOD OF PAYMENT - Indicate the desired method of payment. Make checks p "Drug Enforcement Administration". Third-party checks or checks drawn on foreign be accepted.	ayable to banks will not
	FEES ARE NON-REFUNDABLE.	
	ECTION 9. APPLICANT'S SIGNATURE - Must be the original signature (in ink) of the applicant.	

#### Notice to Registrants Making Payment by Check

Authorization to Convert Your Check: If you send us a check to make your payment, your check will be converted into an electronic fund transfer. "Electronic fund transfer" is the term used to refer to the process in which we electronically instruct your financial institution to transfer funds from your account to our account, rather than processing your check. By sending your completed, signed check to us, you authorize us to copy your check and to use the account information from your check to make an electronic fund transfer from your account for the same amount as the check. If the electronic fund transfer cannot be processed for technical reasons, you authorize us to process the copy of your check.

Insufficient Funds: The electronic funds transfer from your account will usually occur with 24 hours, which is faster than a check is normally processed. Therefore, make sure there are sufficient funds available in your checking account when you send us your check. If the electronic funds transfer cannot be completed because of insufficient funds, we may try to make the transfer up to two times.

Transaction Information: The electronic fund transfer from your account will be on the account statement you receive from your financial institution. However, the transfer may be in a different place on your statement than the place where your checks normally appear. For example, it may appear under "other withdrawals" or "other transactions." You will not receive your original check back from your financial institution. For security reasons, we will destroy your original check, but we will keep a copy of the check for record-keeping purposes.

Your Rights: You should contact your financial institution immediately if you believe that the electronic fund transfer reported on your account statement was not properly authorized or is otherwise incorrect. Consumers have protections under Federal law called the Electronic Fund Transfer Act for an unauthorized or incorrect electronic fund transfer.

NEW INST - Page 3

Form-363	APPLICATION FOR REGISTRATION Supplementary Instructions and Information					
CONTACT INFORMATION	1. INTERNET: 2. TELEPHONE: 3. WRITTEN INQUIR	Headquar	on can be found on our web ters Call Center: (800) 882- present Administration		n.usdoj.gov	
	P.O. Box 28083 Washington DC 20038-8083 4. DEA OFFICES: DEA Offices are listed below (800, 877, and 888 are toll-free numbers).					
ATLANTA DIVISION OFFICE ATTN: Registration 75 Spring Street, SW, Suite 800 Atlanta, GA 30303		DETROIT DIVISION OFFICE 431 Howard Street Detroit, MI 48226		William J. Green Fe 600 Arch Street, Ro	PHILADELPHIA DIVISION OFFICE William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106	
Georgia North Carolina South Carolina	(888) 869-9935 (888) 219-8689 (866) 533-6983	Kentucky Michigan Ohio	(800) 230-6844 (800) 230-6844 (800) 230-6844	Delaware Pennsylvania	(888) 393-8231 (888) 393-8231	
Tennessee BOSTON DIVISION	(888) 219-7898 ON OFFICE	EL PASO DIVISION OFFICE El Paso Federal Justice Center 600 South Mesa Hills Drive, Suite 2000		PHOENIX DIVISION 3010 N. 2nd Street, Phoenix, AZ 85012		
JFK Federal Build 15 New Sudbury Boston, MA 0220	Street, Room E400	El Paso, TX 799 New Mexi∞	12 (915) 832-6014	Arizona SAN DIEGO DIVISI	(800) 741-0902	
Connecticut Maine Massachusetts	(617) 557-2200 (888) 272-5174 (617) 557-2468	HOUSTON DIVI 1433 West Loop Houston, TX 770	South, Suite 600	4560 Viewridge Ave San Diego, CA 921:	nue 23-1637	
New Hampshire Rhode Island Vermont	(888) 272-5174 (617) 557-2200 (888) 272-5174	Texas (S. & Cen	tral) (800) 743-0595 DIVISION OFFICE	California (Southern SAN FRANCISCO 450 Golden Gate Av	DIVISION OFFICE	
CARIBBEAN DIV P.O. Box 2167 San Juan, PR 009		255 East Temple Los Angeles, CA	Street, 20th Floor 190012	P.O. Box 36035 San Francisco, CA	94102	
Puerto Rico U.S. Virgin Island	. ,	California (S. Ce Hawaii Nevada Trust Territory	ntral) (213) 621-6960 (888) 415-9822 (888) 415-9822 (213) 894-2216	California (Northern SEATTLE DIVISION 400 Second Avenue	N OFFICE	
CHICAGO DIVIS Kluczynski Feder 230 S. Dearborn Chicago, IL 6060	al Building Street, Suite 1200	MIAMI DIVISION 8400 N.W. 53rd Miami, FL 33166	Street	Seattle, WA 98119 Alaska Idaho	(888) 219-4261 (888) 219-4261 (888) 219-4261	
Illinois Indiana Minnesota	(312) 353-1234 (312) 353-1236 (312) 353-9166	Florida NEWARK DIVIS	(305) 590-4880	Oregon Washington ST. LOUIS DIVISIO	(888) 219-1418	
North Dakota Wisconsin	(312) 353-9166 (312) 353-1236	80 Mulberry Stre Newark, NJ 071	et, 2nd Floor 02	317 South 16th Stre St. Louis, MO 6310	eet 3	
DALLAS DIVISIO 10160 Technolog Dallas, TX 75220 Oklahoma	y Blvd., East	New Jersey NEW ORLEANS 3838 N. Causew Lakeway III, Suit		lowa Kansas Missouri Nebraska South Dakota	(888) 803-1179 (888) 803-1179 (888) 803-1179 (888) 803-1179 (888) 803-1179	
Texas (Northern)  DENVER DIVISIO  115 Inverness Dri  Englewood, CO 8	ON OFFICE ve, East	Metairie, LA 700 Alabama Arkansas Louisiana	(888) 514-8051 (888) 514-7302 (888) 514-7302	WASHINGTON, D.0 Techworld Plaza 800 K Street, N.W., Washington, D.C. 2		
Colorado Montana Utah Wyoming	(800) 326-6900 (800) 326-6900 (800) 326-6900 (800) 326-6900	Mississippi NEW YORK DIN 99 Tenth Avenue New York, NY 10	•	District of Columbia Maryland Virginia West Virginia	(877) 801-7974 (877) 330-6670 (877) 801-7974 (877) 330-6670	
		New York	(877) 883-5789 (212) 337-1593 (212) 337-1594			

NEW INST - Page 4

Form-363a	RENEWAL APPLICATION FOR REGISTRATION Under the Narcotic Addict Treatment Act of 1974	APPROVED OMB NO 1117-0015 FORM DEA-363a (11-05) Previous editions are obsolete
INSTRUCTIONS	To apply by mail complete this application. Keep a copy for your records.     Print clearly, using black or blue ink, or use a typewriter.     Section 1 should be completed only if your information has changed.     Mail this form to the address provided in Section 7 or use enclosed envelope.     Include the correct payment amount. FEE IS NON-REFUNDABLE.     If you have any questions contact 800-882-9539 prior to submitting your application.     T. Save time - renew online at www.deadiversion.usdoj.gov.	REGISTRATION INFORMATION : DEA # REGISTRATION EXPIRES
	IMPORTANT: DO NOT SEND THIS APPLICATION AND APPLY ONLINE.	
		FEE IS NON-REFUNDABLE
	ICANT TIFICATION	
Business or Facility	Name (if registration is for business entity or is fee exempt)	Δ.
Business or Facility	Name 2 ("doing business as", continuation of business name, or name of fee e	xempt institution)
		THE ALL VALUE OF
Address Line 1 (stre	eet address)	<u> </u>
Address Line 2		
City	VALUE	State Zip Code
Business Phone Nu	mber Business Fax Number	
DEBT COLLECT ON INFORMATION	Tax Identification Number	
Mandatory pursuan		See note #3 on bottom of page 2.
to Debt Collection Improvements Act		
SECTION 2 DRUG SCHEDULES	Schedule II Schedule III	
Check all that apply	Check this box if you require official order forms - for purchase or transfer of so	chedule II controlled substances.
SECTION 3	re you currently authorized by the Food and Drug Administration for the busines	ss activity described in this application?
FDA PERMIT	ES PENDING NO	
Mandatory for approval		FDA Number
SECTION 4 Are the s	you currently authorized to prescribe, distribute, dispense, conduct research, or schedules for which you are applying under the laws of the state or jurisdiction i	otherwise handle the controlled substances in n which you are operating or propose to operate?
STATE LICENSE(S)	YES, I have a license	State License Number
	NOT REQUIRED by this state	License Number
	RENEWAL - Page 1	

<b>-</b>		YES NO	
SECTION 5	I. Has the applicant ever been convicted of a crime in connection with controlled substances under state or federal law?		
LIABILITY	. Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted, or denied?		
IMPORTANT: All questions in this section must	B. Has the applicant ever surrendered (for cause) or had a state professional license or controlled substance registration revoked, suspended, denied, restricted, or placed on probation? Is any such action pending?		
be answered.	4. If the applicant is a corporation (other than a corporation whose stock is owned and traded by th partnership, or pharmacy, has any officer, partner, stockholder, or proprietor been convicted of a controlled substances under state or federal law, or ever surrendered, for cause, or had a federal registration revoked, suspended, restricted, denied, or ever had a state professional license or co- registration revoked, suspended, denied, restricted or placed on probation?	e public), association, crime in connection with Controlled substance ontrolled substance	
EXPLANATION OF "YES" ANSWERS	Date(s) of incident: Location(s) of incident:		
Applicants who have answered "YES" to any of the four question above must provide a statement to explain such answers			
Use this space or attac a separate sheet and return with application	h Result of incident:		
SECTION 6 CERTIFICATION OF EXEMPTION from application fee	Check this box if the applicant is a federal, state, or local government-operated narcotic treatm. Be sure to enter name and address of the exempt institution in Section 1.  The undersigned hereby certifies that the applicant named hereon is a federal, state or local government program, and is exempt from payment of the application fee.		
Provide the name and phone number of the certifying official	Signature of certifying official (other than applicant)  Date		
	Print or type name and title of certifying official Teleph	One No. (required for verification)	
SECTION 7 METHOD OF PAYMENT	Check Make check payable to: Drug Enforcement Administration See page 3 of instructions for important information.	Mail this form with payment to:	
Check one form of payment only	American Express Discover Master Card Visa  Credit Card Number Expiration Date	U.S. Department of Justice Drug Enforcement Administration P.O. Box 28083 Washington DC 20038-8083	
Sign if paying by credit card	Signature of Card Holder	FEE IS NON-REFUNDABLE	
	Printed Name of Card Holder		
SECTION 8	I certify that the foregoing information furnished on this application is true and correct.	,	
APPLICANT'S SIGNATURE	Signature of applicant Da	te	
Sign in ink	Print or type name and title of applicant		
	WARNING: Section 843(a)(4)(A) of Title 21, United States Code states that any person who knowingly or intent fraudulent information in the application is subject to imprisonment for not more than four years, a fine of not more	tionally furnishes false or ore than \$30,000, or both.	
<ol> <li>In accordance with the valid OMB control nutries the time for reviewing</li> <li>The Debt Collection</li> </ol>	Y: Section 302 and 303 of the Controlled Substances Act of 1970 (PL 91-513) and Debt Collection Improv	age 30 minutes per response, including viewing the collection of information. Security Number on this application.	
PURPOSE ROUTINE I	JSES: The Controlled Substances Act Registration Records produces special reports as required for statistica information from this system are made to the following categories of users for the purposes stated: A. Other federal law enforcement and regulatory agencies for law enforcement and regulatory purpose B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purpos C. Persons registered under the Controlled Substances Act (Pt. 91-151) for the purpose of verifying the	al analytical purposes. Disclosures of s. s. ses.	
EFFECT:	Failure to complete form will preclude processing of the application.	-	

\_\_\_\_\_\_

	TION FOR RENEWAL tary Instructions and Information
SECTION 1.	APPLICANT IDENTIFICATION - Entry of missing data or corrections ONLY must be typed or printed in the blocks provided to help reduce data entry errors. Enter changes in previously provided registration information, such as name change, address correction, or new phone numbers.
	Fee exempt applicant should list the name and address of the fee exempt institution.
	A physical address is required; a post office box may be included after the street address.
	Applicant should ensure that the tax identification number (TIN) on record is correct.  Debt collection information is mandatory pursuant to the Debt Collection Improvement Act of 1996.
SECTION 2.	DRUG SCHEDULES - Applicant should check all drug schedules to be handled. However, applicants must still comply with state requirements; federal registration does not overrule state restrictions.
	Check the order form box only if you intend to purchase or to transfer schedule II controlled substances. Order forms will be mailed to the registered address following issuance of a Certificate of Registration renewal.
SECTION 3.	FDA PERMIT - Authorization by the Food & Drug Administration is mandatory for DEA Registration approval. Enter the status of your FDA authorization and the FDA number.
SECTION 4.	STATE LICENSE(S) - Federal registration by DEA is based upon the applicant 's compliance with applicable state and local laws.
	Applicant should contact the local state licensing authority prior to completing this application. Check that you are currently authorized by the state and provide your state license number. If state licensing is not required, indicate "Not required by this state".
SECTION 5.	LIABILITY - Applicant must answer all four questions for the application to be accepted for processing.
	If you answered "Yes" to any question, provide an explanation in the space provided. If additional space is required, you may attach a separate sheet of paper.
SECTION 6.	CERTIFICATE OF EXEMPTION - Exemption from payment of application fee is limited to federal, state or local government-operated narcotic treatment program.
	The applicant's superior or agency officer must certify exempt status. The signature, authority title, and telephone number of the certifying official (other than the applicant) must be provided.
SECTION 7.	METHOD OF PAYMENT - Indicate the desired method of payment. Make checks payable to "Drug Enforcement Administration". Third-party checks or checks drawn on foreign banks will not be accepted.
	FEES ARE NON-REFUNDABLE.
SECTION 8.	APPLICANT'S SIGNATURE - Must be the original signature (in ink) of the applicant.
	Supplemen SECTION 1.  SECTION 2.  SECTION 4.  SECTION 5.  SECTION 6.

#### Notice to Registrants Making Payment by Check

Authorization to Convert Your Check: If you send us a check to make your payment, your check will be converted into an electronic fund transfer. "Electronic fund transfer" is the term used to refer to the process in which we electronically instruct your financial institution to transfer funds from your account to our account, rather than processing your check. By sending your completed, signed check to us, you authorize us to copy your check and to use the account information from your check to make an electronic fund transfer from your account for the same amount as the check. If the electronic fund transfer cannot be processed for technical reasons, you authorize us to process the copy of your check.

Insufficient Funds: The electronic funds transfer from your account will usually occur with 24 hours, which is faster than a check is normally processed. Therefore, make sure there are sufficient funds available in your checking account when you send us your check. If the electronic funds transfer cannot be completed because of insufficient funds, we may try to make the transfer up to two times.

Transaction Information: The electronic fund transfer from your account will be on the account statement you receive from your financial institution. However, the transfer may be in a different place on your statement than the place where your checks normally appear. For example, it may appear under "other withdrawals" or "other transactions." You will not receive your original check back from your financial institution. For security reasons, we will destroy your original check, but we will keep a copy of the check for record-keeping purposes.

Your Rights: You should contact your financial institution immediately if you believe that the electronic fund transfer reported on your account statement was not properly authorized or is otherwise incorrect. Consumers have protections under Federal law called the Electronic Fund Transfer Act for an unauthorized or incorrect electronic fund transfer.

RENEWAL INST - Page 3

\_\_\_\_\_\_

Form-363a APPLICATION FOR RENEWAL Supplementary Instructions and Information CONTACT 1 INTERNET Information can be found on our web site at www.deadiversion.usdoj.gov INFORMATION 2. TELEPHONE: Headquarters Call Center: (800) 882-9539 Drug Enforcement Administration P.O. Box 28083 3. WRITTEN INQUIRIES: Washington DC 20038-8083 DEA OFFICES: DEA Offices are listed below (800, 877, and 888 are toll-free numbers). PHILADELPHIA DIVISION OFFICE William J. Green Federal Building 600 Arch Street, Room 10224 Philadelphia, PA 19106 DETROIT DIVISION OFFICE ATLANTA DIVISION OFFICE ATTN: Registration 75 Spring Street, SW, Suite 800 Atlanta, GA 30303 431 Howard Street Detroit, MI 48226 (800) 230-6844 (800) 230-6844 (800) 230-6844 Kentucky (888) 869-9935 (888) 219-8689 (866) 533-6983 (888) 219-7898 (888) 393-8231 (888) 393-8231 Delaware Georgia Michigan North Carolina South Carolina Pennsylvania EL PASO DIVISION OFFICE PHOENIX DIVISION OFFICE Tennessee El Paso Federal Justice Center 600 South Mesa Hills Drive, Suite 2000 3010 N. 2nd Street, Suite 301 Phoenix, AZ 85012 **BOSTON DIVISION OFFICE** JFK Federal Building 15 New Sudbury Street, Room E400 Boston, MA 02203-0131 El Paso, TX 79912 (800) 741-0902 Arizona (915) 832-6014 New Mexico SAN DIEGO DIVISION OFFICE (617) 557-2200 (888) 272-5174 (617) 557-2468 (888) 272-5174 (617) 557-2200 (888) 272-5174 Connecticut HOUSTON DIVISION OFFICE 4560 Viewridge Avenue San Diego, CA 92123-1637 1433 West Loop South, Suite 600 Houston, TX 77027-9506 Maine Massachusetts New Hampshire California (Southern (800) 284-1152 Rhode Island Texas (S. & Central) (800) 743-0595 SAN FRANCISCO DIVISION OFFICE Vermont LOS ANGELES DIVISION OFFICE 450 Golden Gate Avenue, 14th Floor P.O. Box 36035 CARIBBEAN DIVISION OFFICE 255 East Temple Street, 20th Floor Los Angeles, CA 90012 P.O. Box 2167 San Juan, PR 00922-2167 San Francisco, CA 94102 California (S. Central) (213) 621-6960 California (Northern) (888) 304-3251 (888) 415-9822 (888) 415-9822 Puerto Rico (787) 775-1766 U.S. Virgin Islands (787) 775-1766 Hawaii SEATTLE DIVISION OFFICE 400 Second Avenue, West Seattle, WA 98119 Nevada Trust Territory (213) 894-2216 CHICAGO DIVISION OFFICE Kluczynski Federal Building 230 S. Dearborn Street, Suite 1200 MIAMI DIVISION OFFICE 8400 N.W. 53rd Street Miami, FL 33166 (888) 219-4261 (888) 219-4261 (888) 219-4261 Chicago, IL 60604 ldaho Oregon (312) 353-1234 (312) 353-1236 (312) 353-9166 (312) 353-9166 (312) 353-1236 (305) 590-4880 Washington (888) 219-1418 Indiana Minnesota NEWARK DIVISION OFFICE ST. LOUIS DIVISION OFFICE 80 Mulberry Street, 2nd Floor Newark, NJ 07102 317 South 16th Street St. Louis, MO 63103 North Dakota Wisconsin DALLAS DIVISION OFFICE (888) 803-1179 (888) 803-1179 (888) 803-1179 (888) 803-1179 (888) 356-1071 New Jersev lowa 10160 Technology Blvd., East Dallas, TX 75220 Kansas NEW ORLEANS DIVISION OFFICE 3838 N. Causeway Blvd Lakeway III, Suite 1800 Metairie, LA 70002 Missouri Nebraska Oklahoma (888) 336-4704 Texas (Northern) (888) 336-4704 South Dakota (888) 803-1179 WASHINGTON, D.C. DIVISION OFFICE DENVER DIVISION OFFICE 115 Inverness Drive, East Englewood, CO 80112 (888) 514-8051 (888) 514-7302 (888) 514-7302 (888) 514-7302 Techworld Plaza 800 K Street, N.W., Suite 500 Washington, D.C. 20001 Alabama Arkansas Mississippi (800) 326-6900 (800) 326-6900 (800) 326-6900 (877) 801-7974 (877) 330-6670 (877) 801-7974 Colorado District of Columbia NEW YORK DIVISION OFFICE 99 Tenth Avenue New York, NY 10011 Montana Maryland Utah Virginia Wyoming (800) 326-6900 West Virginia (877) 330-6670 (877) 883-5789 (212) 337-1593 (212) 337-1594 New York

RENEWAL INST - Page 4